Title: A Methodological Review of Patient Healthcare-Seeking Journeys from Symptom Onset to Receipt of Care

Authors:

Charity Oga-Omenka^{1,2}, Angelina Sassi^{2,3}, Nathaly Aguilera Vasquez^{2,} Namrata Rana^{2,4}, Mohammad Yasir Essar^{2,4}, Darryl Ku¹, Hanna Diploma¹, Lavanya Huria^{2,3}, Kiran Saqib¹, Rishav Das², Guy Stallworthy⁵, Madhukar Pai^{2,3}

Affiliations:

- 1. School of Public Health Sciences, University of Waterloo, Ontario, Canada
- 2. McGill International TB Centre, Montreal, Canada
- 3. School of Population and Global Health, McGill University, Montreal, Canada
- 4. Faculty of Health Sciences, McMaster University
- 5. Bill and Melinda Gates Foundation

Key Questions

What is already known about this subject?

- Accessing healthcare is challenging for half of the world's population.
- Understanding healthcare-seeking obstacles can help to expose bottlenecks in healthcare delivery and improve access.

What does this study add?

- We synthesized the different methodologies used by researchers to portray healthcareseeking trajectories.
- We also provide a conceptual framework and recommendations for patient journey analyses.

How do the new findings imply?

- Our analysis revealed a lack of consistency in how patient journeys to care are represented and a notable complexity in generating insightful depictions of journeys to care.
- The use of our conceptual framework, namely the data points and indicators, could increase the reliability and generalisability patient journey analyses.

2 Abstract

3 **Background:** For many diseases, early diagnosis and treatment are more cost-effective, 4 reduce community spread of infectious diseases, and result in better patient outcomes. 5 However, healthcare-seeking and diagnoses for several diseases are unnecessarily delayed. 6 For example, in 2022, 3 million and 5.6 million people living with TB and HIV respectively 7 were undiagnosed. Many patients never access appropriate testing, remain undiagnosed after 8 testing or drop out shortly after treatment initiation. This underscores challenges in accessing 9 healthcare for many individuals. Understanding healthcare-seeking obstacles can expose 10 bottlenecks in healthcare delivery and promote equity of access. We aimed to synthesize 11 methodologies used to portray healthcare-seeking trajectories and provide a conceptual 12 framework for patient journey analyses.

13 Design/Methods: We conducted a literature search using keywords related to "patient/care

14 healthcare-seeking/journey/pathway analysis" AND "TB" OR "infectious/pulmonary

15 diseases" in PubMED, CINAHL, Web of Science and Global Health (OVID). From a

16 preliminary scoping search and expert consultation, we developed a conceptual framework

17 and honed the key data points necessary to understand patients' healthcare-seeking journeys,

18 which then served as our inclusion criteria for the subsequent expanded review. Retained

19 papers included at least three of these data points.

Results: Our conceptual framework included 5 data points and 7 related indicators that contribute to understanding patients' experiences during healthcare-seeking. We retained 66 studies that met our eligibility criteria. Most studies (56.3%) were in Central and Southeast Asia, explored TB healthcare-seeking experiences (76.6%), were quantitative (67.2%), used in-depth, semi-structured, or structured questionnaires for data collection (73.4%). Healthcare-seeking journeys were explored, measured and portrayed in different ways, with no consistency in included information.

27 Conclusions: We synthesized various methodologies in exploring patient healthcare-seeking 28 journeys and found crucial data points necessary to understand challenges patients encounter 29 when interacting with health systems. and offer insights to researchers and healthcare 30 practitioners. Our framework proposes a standardized approach to patient journey research.

31 Introduction

32 In 2021, 4.5 billion people or more than half of the world's population lacked access to the healthcare they needed.¹ Diagnoses for several diseases are unnecessarily delayed, 33 34 contributing to prolonged suffering and avoidable deaths. For example, in 2022, an estimated 3 million and 5.6 million people living with TB and HIV respectively were undiagnosed.^{2,3} 35 36 A significant number of individuals with life-threatening illnesses never access appropriate 37 testing, remain undiagnosed after testing or drop out before or shortly after treatment initiation. ⁴⁻⁷ Some reasons for these gaps in testing, diagnosis, and treatment include 38 39 individual and interpersonal dynamics like lack of information about the disease and 40 available resources, stigma, financial and cultural factors, symptom minimization, selfmedication and mistrust of public sector healthcare⁸⁻¹³; as well as health system factors like 41 poor coverage of services, low index of suspicion among providers, lengthy procedures, 42 misdiagnosis, and poor referral mechanisms between the public and private sectors.^{10,14-16} 43 44 These numbers underscore the substantial public health challenge that accessing healthcare 45 poses for many individuals. Despite these barriers, early diagnosis and treatment remain 46 critical for significantly improving clinical outcomes and reducing costs for both patients and 47 the healthcare system, especially for infectious diseases like TB and HIV where early intervention is the most practical method to interrupt transmission.^{10,17} 48

49 The World Health Organization (WHO) adopted the integrated people-centered health 50 services framework in 2016 to prioritize people's needs and expectations by engaging 51 communities, reorienting models of care, coordinating services across sectors and strengthening governance and accountability.¹⁸⁻²⁰ Person-centered care emphasizes treating 52 53 patients as individuals and focuses on providing integrated care, patient information and support, and responding to patients' values and preferences.^{21,22} To improve person-centered 54 care, it is important to understand current patient journeys to care 23 . These studies shed light 55 56 on the obstacles patients encounter during healthcare-seeking, expose healthcare delivery bottlenecks and promote equitable access.²⁴⁻²⁶ Understanding patient journeys is critical for 57 making services more patient focused, by identifying gaps in service delivery to ensure 58 quality care is accessible early in the healthcare-seeking process.^{12,27-29} While patient 59 pathways analyses are emerging, lack of consistency in methods, or shared terms and 60 61 frameworks makes it difficult to interpret across settings. Our review aimed to synthesize 62 methodologies used to portray patients' healthcare-seeking trajectories and provide a clear

conceptual framework for patient journey analyses. In this review, we have explored
methodologies used to highlight patient healthcare-seeking experiences from various disease
contexts, including TB.

While also commonly referred to as patient pathways in literature, the healthcare-seeking journey analysis emphasized in this paper differs from the process analytics used to map and improve integration for in-hospital processes between the different departments³⁰⁻³³ or the pathway analysis to determine alignment between population health needs and available services.^{34,35} Patient journey analyses characterize and quantify the pathways to care of specific patients, detailing not only the total delays between key milestones³⁶⁻³⁹ but also the number and sequence of visits to healthcare providers.^{27-29,40}

73 Current literature has yet to explore the advantages and limitations of different methods of 74 depicting healthcare-seeking trajectories and identifying the key variables that highlight these 75 obstacles. The combination of conceptual and methodological reviews has been used widely in literature to critically appraise different research methods.⁴¹⁻⁴³ A conceptual review is 76 77 focused on key data points or variables and their relationships, with the goal of categorizing and describing them relevant to a particular topic.⁴⁴⁻⁴⁶ Methodological reviews differ from a 78 traditional systematic review by prioritizing methods over results,⁴⁷⁻⁵⁰ synthesizing study 79 quality by examining design, data collection and analysis.^{47,48} This review aims to synthesize 80 81 methods for portraying patients' trajectories for TB and other diseases and propose a 82 conceptual framework for analyzing these journeys.

83 Methods

84 **Review Objectives**

The primary aim of our review was to assess relevant current practices, methodologies and relevant data points used to map patient care trajectories for TB and related diseases, focusing on the patient healthcare-seeking journey from symptom onset to care outcome across diverse healthcare settings and conditions. The research question was: 'How do the methodologies employed for patient journey analysis (PJA) differ, what are their strengths and limitations?'.

90 **Review Approach**

91 We use the conceptual and methodological review approaches, which adapt their scope and 92 methods during the process.^{48,50} We used an iterative approach, using literature review and 93 expert consultations to understand the patient healthcare-seeking journey. This entailed

94 extensive database searches and consultations with experts in tuberculosis care and social

95 science, and refining review findings based on iterative feedback.

96 Search Strategy and Framework Development

97 Our process comprised of three steps: (1) A scoping literature search to identify relevant data

- 98 points and methods; (2) Expert consultation to identify conceptual papers and recommended
- 99 measures, followed by the development of conceptual map; and (3) An updated literature
- 100 search targeting papers that included identified data points.
- 101 *Initial scoping literature search*

We performed a scoping search on PubMed, Web of Science, Scopus, and Google Scholar for publications on healthcare-seeking trajectories and delays related to TB diagnosis or treatment. The initial search was run in November 2021 (updated later, see below) and was restricted to peer-reviewed publications in the English language with no date restrictions. We also consulted with TB care experts to identify additional papers.

107 *Development of the conceptual framework*

108 Our conceptual framework was derived from the initial literature search followed by expert 109 consultations. The lead author reviewed the literature and identified multiple criteria-110 variables, factors, and themes-that describe and influence patients' journeys to care. The research team had several meetings to discuss, clarify, and define the key features to be 111 112 included in the framework, culminating in developing the first draft. To validate the 113 framework, the team sought expert consultation from experienced researchers and healthcare 114 professionals in the field of TB and HIV care in several meetings, workshops, and 115 conferences to identify additional data points, and ensure a comprehensive understanding of 116 key methodological considerations. The conceptual framework, identifying key variables or 117 themes for two care outcomes - diagnosis and treatment, was refined based on feedback from 118 these interactions and used to define the inclusion criteria. As a result of this process, we 119 decided to expand our initial literature search to cover methodologies used to describe patient 120 healthcare-seeking journeys for infectious or pulmonary diseases, or diseases with non-121 specific symptoms or lengthy diagnostic procedures - including HIV, COVID, malaria and 122 cancer, to strengthen the insights gained from this methodological review beyond what could 123 be inferred from TB research alone. Defining the conceptual framework helped with the rest 124 of the methodological review to identify the lack of consistency in methods and analytic 125 approaches.

126 Updated literature search and inclusion criteria

We systematically searched PubMed, CINAHL, Web of Science, Global Health (OVID), and Scopus for publications on healthcare-seeking trajectories, delays to diagnosis or treatment, and access to diagnosis or treatment, for TB, HIV, malaria, COVID-19, and other respiratory and lung disorders. The initial search of November 2021 was updated in April 2022 and searched again in May 2023. Our search strategy can be found in *Supplement 1*.

132 To be included in our review, studies had to include at least three of the identified data points 133 for assessing patient journeys within the healthcare system in low- and middle-income 134 countries (Table 1). We excluded case studies of individuals; non-scientific publications such 135 as opinions or editorials; systematic reviews and meta-analyses; studies on extrapulmonary 136 tuberculosis (EPTB), latent TB, and pediatric TB (children under 15 years); studies focusing 137 solely on the cascade of care; articles written in languages other than English or French; and 138 articles that did not provide a full report of the results of an experimental study (abstract, 139 reviews, commentaries, proposals, methodology papers, or case study).

140 References retrieved from all databases were imported into Covidence. Title and abstract 141 screening were carried out by five members of the team (NAV, COO, DK, AS, and MYE) 142 and full-text screening by four members of the team (COO, LH, NAV, and MYE), meeting 143 regularly to review progress and resolve conflicts. Agreement on inclusion between two 144 reviewers was required for inclusion into the study. Conflicts were resolved by a third 145 reviewer when necessary.

146 There are no clear guidelines for appraising the quality and risk of bias for methodological reviews.^{47,48} The focus of the appraisal process for this type of review should be on 147 distinguishing between papers stemming from flawed empirical studies and those presenting 148 well-argued theories.⁴⁷ We used the JBI Critical Appraisal Checklists⁵¹ for each applicable 149 150 study type (qualitative, cross-sectional, cohort, or prevalence study) and the Mixed Methods Appraisal Tool⁵² for mixed-methods studies to evaluate the methodological rigor and 151 152 reliability of the included studies and identify potential biases and limitations within the 153 studies. Quality assessment was carried out by six members of the team (AS, NAV, RD, DK, 154 MYE, and KS) using an electronic form which was piloted by AS and NR (Supplement 3). 155 Quality assessment for each paper was done by two independent reviewers and answers were 156 finalized during a consensus meeting led by AS and MYE.

157 Data extraction

158 Data extraction was done by six members of the team (AS, MYE, NR, DK, HD, and CO) 159 using an electronic data extraction form hosted on Covidence (Supplement 2). The data 160 extraction form was piloted by CO, NAV, LH, and NR prior to data extraction. The data 161 extraction form aimed to collect general information (author name, publication year, 162 country/setting, disease type, study design/data sources, study type and sample size), the 163 journey criteria included for diagnosis and treatment, a general description of the 164 methodology and analysis for each study, as well as strengths and limitations. Data extraction 165 for each paper was done by two independent reviewers, and answers were finalized during a 166 consensus meeting led by AS and MYE.

- 167 Ethical considerations
- 168 No human participants were involved in this review.

169 Funding and conflicts of interest

- 170 This work was supported by the McGill International TB Centre with funding from the Bill &
- 171 Melinda Gates Foundation (BMGF) [grant number INV-022420], and by the School of
- 172 Public Health Sciences, University of Waterloo. MP was also supported by a Canada
- 173 Research Chair award from the Canadian Institutes of Health Research (CIHR). The CIHR
- 174 did not have any role in the conceptualization or writing of the manuscript or in the decision
- to submit it for publication. GS, a co-author of this manuscript and an employee of the
- 176 BMGF provided valuable inputs on the study design, analysis, and revision of the
- 177 manuscript. MP serves as an advisor to several non-profit organizations including Bill &
- 178 Melinda Gates Foundation, WHO, Stop TB Partnership and FIND. He has no financial or
- 179 industry conflicts. All other authors declare no conflicts of interest. The authors were not
- 180 precluded from accessing data in the study and accept responsibility to submit for
- 181 publication.

182 **Results**

183 Definition of Key Data points and the Conceptual Map

The care continuum describes the sequence of activities needed to be fully engaged in clinical care for diseases like TB and HIV that requiring lengthy health system procedures to achieve an outcome.⁵³⁻⁵⁵ Our patient journey framework, developed after the initial review of literature, highlights the patient healthcare-seeking trajectory across three reference points: symptom recognition, diagnosis, and treatment initiation. Our review illustrates how patients consult various types of providers in differing numbers as they seek care between these

190 reference points. To characterize each visit within a patient's journey, we identified five key 191 data points: (1) the date of the first visit relative to symptom onset, (2) the type of provider or 192 facility visited (e.g., chemist, general practitioner, specialist, laboratory, hospital), (3) the 193 sector of the provider or facility (for-profit, non-profit, public), (4) the sequence of the visit 194 (first visit, second visit, etc.), and (5) the outcome of the visit (no outcome, diagnosis, 195 treatment initiation). Using these data points, we can compute various indicators for both 196 individual patients and aggregated patient populations. These measures include (1) the 197 number of days and (2) visits until care outcome (diagnosis or treatment initiation), (3) the 198 proportion of visits to different types of providers, (4) the contribution of various provider 199 types to care outcome (diagnosis or treatment) as well as to (6) delays or missed 200 opportunities, and (7) the number of patients exhibiting different patterns or sequences of 201 provider visits. This comprehensive analysis can inform strategies to optimize patient care 202 experiences and reduce delays in diagnosis and treatment.

203

204 Figure 1: Conceptual framework of healthcare-seeking journeys

205

206 Our conceptual framework (Figure 1) illustrates the steps in a patient journey and the time 207 delays between key milestones of symptom recognition, diagnosis, and treatment. Starting 208 with symptom recognition, factors like symptom minimization and lack of knowledge of 209 services have been shown to influence healthcare-seeking delays, while the type and sector of 210 first provider have been shown to influence number of subsequent encounters before and timeliness of diagnosis.^{10,11,56,57} Several health system factors have been shown to influence 211 212 the timing and number of encounters between the reference points of diagnosis and treatment.^{10,11,58} Delays are conceptualized as healthcare-seeking, provider and treatment 213 214 delays, with diagnostic delays being the sum of healthcare-seeking and provider delays, and health system delays representing the sum of provider and treatment delays.^{27,29} 215

216

217 *Table 1 – The key data points of patient healthcare-seeking journey*

- 218
- 219

220 **Characteristics of Included Studies** 221 The PRISMA flow diagram (Figure 2) shows search results from the five main databases. 222 Out of the 12160 studies whose titles and abstracts were initially screened from those 223 databases, 297 studies were assessed for retrieval and eligibility, 231 were excluded through 224 full-text review, and 66 studies were retained that met our eligibility criteria. Each of these 66 225 studies (our unit of analysis) was a patient journey analysis publication. 226 Out of the 66 retained studies, we assessed 21 to be of high quality, 37 to be medium quality, 227 and 8 to be of low quality. There were no major differences in the methods for the studies 228 assessed with different qualities. 229 230 Figure 2 – Prisma diagram of study selection process 231 232 Table 2 summarizes journey methodology characteristics of included studies. Many studies 233 were quantitative (82%), were conducted in lower middle-income countries (56%), in Asia 234 (59%), and covered TB care journeys (67%). Other diseases include the following: cancer 235 (6.1%), acute febrile illnesses (4.5%), malaria (4.5%), chest symptomatic (3.0%), multiple 236 infectious diseases (3.0%), non-communicable diseases (3.0%), sexually transmitted 237 infections (3.0%), under-five mortality (3.0%), and COVID-19 (1.5%). 238

239 Table 2: Characteristics of included manuscripts

240

241 Figure 3a summarizes the distribution of patient healthcare-seeking data points aggregated 242 across all included studies. The majority included information on location/provider where 243 treatment was initiated (67%), sector of the providers visited (61%), time to diagnosis (56%), 244 location/provider where a diagnosis was made (55%), number of provider encounters to 245 diagnosis (53%), and type of the providers visited (50%). Proportions of patients per number 246 of encounters to diagnosis (33%) and treatment (20%), and number of provider encounters to 247 treatment (30%) were less commonly explored in the included papers. Figure 3b shows that 248 most of the patient healthcare-seeking data points were reported within studies the four 249 disease groups. Type of facility/provider where treatment was started is more frequently 250 found in articles focused on malaria and fevers and other infectious diseases compared to

other disease types. Most categories of data were available in all types of study design
(*Figure 3b*).

Figure 3: Distribution of journey data points across all included studies, by disease types and
study designs

255

Table 3 details the depictions of healthcare-seeking journeys and statistical methods used in the included studies. The most common forms of depicting patient healthcare-seeking journeys were tables quantifying delays and/or journeys (48%) and flowcharts (48%).
Descriptive statistics (88%), multivariate regressions (45%), chi-squared test (45%), and logistic regression (36%) were the most frequently used statistical methods.

261

262 Table 3: Journey depictions and statistical methodologies

263

264 Table 4 depicts the outcome measures and independent variables used in the included 265 articles. Overall, patient delay (58%) was the most common outcome measure for the 66 266 included studies. Over one-third (42%) of included articles did not report all possible delays 267 that could have been reported in the manuscript; for example, if the authors reported diagnostic delay (defined^{27,29} as the number of days between the onset of symptoms and the 268 269 date of diagnosis and composed of patient delay and provider delay) but did not also report 270 both patient and provider delay. Other than overall delay, the most reported outcome 271 measures of patient journeys were number of visits to diagnosis (36%), sector of facility and 272 type of provider for all instances of healthcare-seeking (36% and 33%, respectively), and 273 type of provider for initial healthcare-seeking visit (32%). Time to initial healthcare-seeking 274 was reported in 29% of included studies. Patient age (97%) and sex or gender (92%) were the 275 two most used independent variables among the 66 included studies, followed by level of 276 education (62%) and occupation (59%). Among patient health status and patient behavior 277 variables, type of disease (30%), presence of any comorbidities (27%), and HIV status (27%) 278 were often included as independent variables. Some patient healthcare-seeking journey 279 characteristics were used as independent variables in analyses of delays, for example, number 280 of visits (30%), sector of facility (39%) and type of provider (38%) of initial healthcare-281 seeking visit.

283 Table 4 – Outcome measures and independent variables used.

284 **Discussions**

285 In our review, we aimed to understand and characterize methodologies used to assess patient

- 286 journeys to care. Understanding patient journeys helps pinpoint bottlenecks and interventions
- to minimize missed diagnostic and treatment opportunities among various types of healthcare
- 288 providers, improve hospital coordination and reduce overall delays in care. Moreover,
- accurately characterizing aggregate patient journeys between different locations or across
- 290 different times enhances progress monitoring and policymaking. This requires developing
- better, consistent metrics and more insightful data visualizations.
- 292 Our analysis revealed a lack of consistency in how patient journeys to care are represented
- and a notable complexity in generating insightful depictions of journeys to care, indicating
- the challenges in using data to guide healthcare interventions effectively. The scarcity of
- tools and clear guidelines for analyzing and presenting such complex data further complicates
- this task, highlighting an urgent need for simple, open-access tools and standardized
- analytical methods to improve our understanding of patient healthcare-seeking journeys.
- 298 We posit that our proposed conceptual framework, identified data points and indicators
- address this knowledge gap effectively, offering guidance to improve consistency in the
- analysis of patient journey or healthcare-seeking experiences.
- 301 The reviewed papers typically addressed an average of four identified key data points, with
- 302 patient delays, and the type or sector of facility where the patient was diagnosed or treated
- being the most often examined. We also noted that the number of provider visits needed for
- diagnosis or treatment were only reported in 24% and 12% respectively. In our view, the
- 305 number of visits to diagnosis and treatment are among the most important data points for
- 306 understanding patient care barriers, as both give us an insight into delays as well as the direct
- and indirect costs of care. Overall, as none of these factors alone fully characterize patient
- 308 experiences, or highlight missed diagnostic and treatment opportunities, reporting all data
- 309 points relevant to the outcome under review (diagnosis or treatment) is crucial for a
- 310 comprehensive view of patient care journeys. Thus, our methodological review highlighted
- 311 the key features of patient trajectories (*Table 1*) that offer insights into the missed
- 312 opportunities. Additionally, we recommend additional statistical analyses to identify risk
- factors for having more provider visits or longer delays in the patient care continuum using

314 patients' sociodemographic characteristics and health status (*Table 4*). We propose the need

for an open source analysis package for Patient Journey Analyses.

316 Strengths and limitations of study designs

317 We assessed the strengths and limitations for each study design. Cross-sectional studies provide overview of patient proportions and care-seeking behaviours and quantify patient 318 319 proportions between visits or delays. Still, varying tools and measures across studies can 320 make collating results challenging and lead to inconsistencies. Cohort studies excel in 321 examining care-seeking behaviors over time and identifying risk factors for delays, providing 322 insights into temporal relationships and complex journeys, though they require large sample 323 sizes and are also vulnerable to recall bias, especially in studies of diseases with low 324 prevalence.

Despite being more resource-intensive, mixed methods research combines quantitative data with rich qualitative insights from key informants. Qualitative research delves deep into the experiences and obstacles within patient journeys, offering flexibility in adapting to different contexts, but is similarly limited by recall bias, high costs, and small sample sizes.

329

330 Implications for Future Research

331 Patient journey analyses are prone to potential inconsistencies in data collection, particularly 332 regarding sampling of patients, measuring encounters by number of providers or visits, and 333 the measurement of time reference points (symptom onset, diagnosis, and treatment). Future 334 research should focus on developing clear, practical recommendations for conducting patient 335 journey analyses and creating open-access tools to overcome methodological and resource 336 limitations. These advancements are crucial for researchers and teams aiming to analyze 337 patient journeys effectively to identify and address care bottlenecks. Learning from our 338 experiences and adopting these strategies will improve the reliability and comparability of 339 patient journey analyses in future studies.

To mitigate recall bias, researchers need to pilot test study instruments, train data collection teams, employ specific sampling strategies (e.g., recruiting patients diagnosed within the last six months), and utilize data triangulation, including mixed methods and comparison to earlier studies where possible. Additionally, data collectors need to be creative in helping patients recall key dates, e.g. with use of local or national events, and/or use clinical records to verify patient-reported dates, where feasible.


346 Conceptually, incorporating patient cost surveys into journey analyses is another opportunity 347 for a comprehensive understanding of patient care barriers, particularly where these include 348 incurred costs for all healthcare provider visits. Cost surveys are often conducted by 349 economists with a primary focus on cost analysis, and rarely provide detailed insights into the 350 nuances of patient journeys. Conversely, patient journeys analyses rarely include cost data. 351 This disconnect between cost analysis and journey mapping presents a significant gap in the 352 literature and integrating both aspects could provide a more holistic view of patient 353 experiences and economic impacts. To address this gap, we recommend that future patient 354 cost surveys be designed to enable rigorous analysis of patient journeys, and vice versa. Such 355 an approach would facilitate a better understanding of both the financial and experiential data 356 points of patient care-seeking behaviours. Ultimately, this dual-focus approach could 357 significantly enhance the quality of insights derived from patient surveys, leading to 358 improved patient-centric service delivery and better-informed healthcare policy decisions.

359 Conclusions

360 Our findings underscore the critical need for better approaches to compare patient journeys 361 and develop interventions, emphasizing the importance of clear guidelines and accessible 362 tools to facilitate this analysis. This work lays the groundwork for future efforts to enhance 363 access, quality, and equity in healthcare service provision.

365 Figures and Tables






368 Figure 1: Conceptual framework of healthcare-seeking journeys

Reference points	Data points	Purpose	How to measure (quantitatively and qualitatively)	Studies
Symptoms recognition	Date symptoms started	To determine the time when symptoms started or when patients recognized their symptoms	This is a date variable. Can also be expressed in time increments (e.g., weeks, months, etc.).	28,59-91
	Type of provider first visited after symptom onset	To identify the first healthcare provider that patients sought for their symptoms until diagnosis after recognition	E.g. physician, nurse, pharmacist, laboratory technician, medicine vendor	28,60-65,68,69,79,82,84-88,90-106
	Sector of facility first visited	To specify type of facility for that encounter	E.g. private sector, public sector, or informal sector	28,60-65,68,79,84-88,90-106
	Date of (or time to) diagnosis	To determine how long it took for patients to get diagnosed	This is a date variable. Can also be expressed in time increments (e.g., weeks, months, etc.).	28,59-91,93,96
	Number of provider encounters to diagnosis	To identify the number of visits it took for patients to go from the first encounter until diagnosis	1st encounter, 2nd encounter, etc.	28,40,59-64,67,69,71-73,77,79,81,83,84,86,88,90- 93,96-98,102,103,105,107-110
Symptom recognition to	Type of provider for each encounter to diagnosis	To specify the type of provider the patients saw at each encounter	E.g. physician, nurse, pharmacist, laboratory technician, medicine vendor	28,60,63-65,68,69,79,82,84-88,90-106,111
Diagnosis	Sector of facility for each encounter	To specify type of facility for where patients were diagnosed	E.g. private sector, public sector, or informal sector	28,60,63-65,68,79,84-88,90-106,111
	Proportions of patients per number of encounters to diagnosis	To determine the proportion of patients who had that many encounters. Also helps to identify missed opportunities for that provider	Expressed as % of 1st encounter, 2nd encounter, etc.; or number of patients at each reference point, e.g. "20% of patients had 1-2 encounters, 30% had 3 encounters"	28,60,62,63,66,73,77,79,83,87,88,91,92,95,98,102,10 3,108,110,112
Diagnosis to treatment	Date of (or time to) treatment initiation	To determine how long it took for patients to start treatment once diagnosed	This is a date variable. Can also be expressed in time increments (e.g., weeks, months, etc.).	28,60-66,68-73,75-77,80,81,85-87,89,93- 96,103,105,112-118

369 Table 1 – The key data points of patient healthcare-seeking journey

Number of provider encounters to treatment initiation	To identify the number of visits to a provider that it took for patients to start treatment after diagnosis.	1st encounter, 2nd encounter, etc.	60,63,72,75- 77,81,85,87,93,94,96,99,101,103,105,110,114,115,11 7
Type of provider for each encounter to treatment initiation Sector of facility for each encounter to treatment initiation	To specify the type of provider the patients saw at each encounter	laboratory technician, medicine vendor E.g. private sector, public sector, or	60- 63,85,87,88,90,91,93,94,96,99,101,103,105,111,113,1 19-121 60,63,85,87,88,90,91,93,94,96,99,101,103,105,119- 121
Proportions of patients per number of encounters to treatment initiation	To determine the proportion of patients who had that many encounters. Also helps to identify missed opportunities for that provider	Expressed as % of 1st encounter, 2nd encounter, etc.; or number of patients at each reference point, e.g. "20% of patients had 1-2 encounters, 30% had 3 encounters"	62,63,76,83,85,87,93,95,105,110,112,120



371 Figure 2 – Prisma diagram of study selection process


372

370

373 Table 2: Characteristics of included manuscripts


Characteristic	$N = 66^{1}$
Year of publication	2017 (1997 – 2022)
Region	
Asia (Bangladesh, China, India, Indonesia, Nepal, Singapore, Syrian Arab	39 (59%)
Republic, Taiwan, Tajikistan, Thailand)	
Africa (Burkina Faso, Ethiopia, Gambia, Kenya, Malawi, Mozambique,	19 (29%)
Nigeria, Senegal, South Africa, Uganda, Zimbabwe)	
Oceania (Australia, Vanuatu)	3 (4.5%)
Americas (Brazil, Canada)	2 (3.0%)
Europe (Switzerland, UK)	2 (3.0%)
Multi-country (France, Germany, Japan, United States)	1 (1.5%)
Income level	

Characteristic	$N = 66^{1}$
Low income	10 (15%)
Lower middle income	37 (56%)
Upper middle income	11 (17%)
High income	8 (12%)
Low to middle income (multi-country)	0 (0%)
Disease	
Tuberculosis	44 (67%)
Cancer	4 (6.1%)
Acute febrile illnesses	3 (4.5%)
Malaria	3 (4.5%)
Non-communicable diseases	3 (4.5%)
Chest symptomatic	2 (3.0%)
Multiple infectious diseases	2 (3.0%)
Sexually transmitted infections	2 (3.0%)
Under-five mortality	2 (3.0%)
COVID-19	1 (1.5%)
Study design	
Cross-sectional study	51 (77%)
Qualitative Research	7 (11%)
Mixed Methods	5 (7.6%)
Cohort Study	3 (4.6%)
Data type	
Quantitative	54 (82%)
Qualitative	7 (11%)
Mixed	5 (7.6%)
Quality appraisal	
Low quality	8 (12%)
Medium quality	37 (56%)
High quality	21 (32%)
Total sample size	283 (26 – 23,961)
Number of male participants ^{2,3}	186 (2 – 12,987)
Number of female participants ^{2,4}	100 (12 – 10,974)
¹ Median (Range); n (%)	
² Sex of participants unspecified (n=4)	
³ Only women included (n=1)	
⁴ Only men included (n=1)	



100 75 Patient journey data points Type of provider for each encounter Sector of facility for each encounter Number of provider encounters to diagnosis Proportions of patients per number of encounters to diagnosis Hercent 50 Time to diagnosis Location/provider where diagnosis was made Number of provider encounters to treatment Proportions of patients per number of encounters to treatment Time to treatment Location/provider where treatment was made 25 Ó Cancer/NCDs Malaria/Fevers Other Tuberculosis/Chest symptomatic (n=46) (n=7) (n=6) (n=7) Disease Figure 3b: Coverage of patient journey data points by disease studied

Figure 3a: Distribution of patient healthcare-seeking journey data points



- 375 Figure 3: Distribution of journey data points across all included studies, by disease types and
- 376 *study designs*

377

378 Table 3: Journey depictions and statistical methodologies

Characteristic	$N = 66^{1}$
Depictions of patient journeys to care	
Tables quantifying delays/journeys	32 (48%)
Flow chart	32 (48%)
Bar chart	12 (18%)
Authors' own depiction (other)	9 (14%)
Matrix representing patient journeys	6 (9.1%)
Diagram summarizing types of delays	5 (7.6%)
Sankey chart	3 (4.5%)
Scatter plot	1 (1.5%)
Statistical methodologies used	
Main statistical method used per article	
Logistic regression only	18 (27%)
Chi-square test only	7 (11%)
Independent T-test and Chi-square test only	7 (11%)
More than one regression method	7 (11%)
Thematic analysis only	7 (11%)
Descriptive statistics only	5 (7.6%)
Independent T-test only	5 (7.6%)
Mixed methods	4 (6.1%)
Linear regression only	3 (4.5%)
Analysis of variance (ANOVA) test only	1 (1.5%)
Quantile regression only	1 (1.5%)

Survival analysis only	1 (1.5%)
Descriptive statistics	58 (88%)
Chi-squared test	30 (45%)
Independent T-test	22 (33%)
Fisher's exact test	8 (12%)
Mann-Whitney test	8 (12%)
Kruskal-Wallis test	4 (6.1%)
Analysis of variance (ANOVA)	3 (4.5%)
Multivariate regression (all types)	30 (45%)
Logistic regression	24 (36%)
Linear regression	8 (12%)
Survival analysis	3 (4.5%)
Poisson regression	2 (3.0%)
Quantile (median) regression	2 (3.0%)
Thematic analysis of qualitative data	11 (17%)
¹ n (%)	

379

380

381 Table 4 – Outcome measures and independent variables used

Туре	Variable	$N = 66^{1}$
Outcome	Delays	
measures	Healthcare-seeking or patient delay	38 (58%)
	Provider delay	15 (23%)
	Treatment delay	16 (24%)
	Diagnostic delay	18 (27%)
	Health system delay	14 (21%)
	Total delay	18 (27%)
	Manuscript did not report all possible delay components	28 (42%)
	Manuscript reported "durations" and defined "delays" as durations above a given threshold	11 (17%)
	Patient journey data points	
	Number of visits to diagnosis	24 (36%)
	Number of visits to treatment initiation	12 (18%)
	Type of provider for all instances of healthcare-seeking	22 (33%)
	Sector of facility for all instances of healthcare-seeking	24 (36%)
	Type of provider for initial healthcare-seeking visit	21 (32%)
	Sector of facility for initial healthcare-seeking visit	15 (23%)
	Type of provider for place of diagnosis	5 (7.6%)
	Sector of facility for place of diagnosis	8 (12%)
	Type of provider for place of treatment	4 (6.1%)
	Sector of facility for place of treatment	6 (9.1%)
	Patient sought care for their symptoms	3 (4.5%)
	Number of visits (in general)	4 (6.1%)

Туре	Variable	$N = 66^{1}$
	Time and date measures	
	Time to initial healthcare-seeking	19 (29%)
	Time to diagnosis	17 (26%)
	Time to treatment	11 (17%)
	Date of symptom onset	5 (7.6%)
	Date of initial healthcare-seeking	6 (9.1%)
	Date of diagnosis	5 (7.6%)
	Date of referral for treatment	3 (4.5%)
	Date of treatment initiation	3 (4.5%)
	Date of treatment completion	2 (3.0%)
	Survival analysis (time to event/death)	2 (3.0%)
	Others	
	Costs of care (at any point)	11 (17%)
	Reasons for seeking care	5 (7.6%)
	Disease prevalence	3 (4.5%)
	Patient knowledge of disease	2 (3.0%)
	Qualitative study	4 (6.1%)
Independent	Demographic characteristics	
variables	Age	64 (97%)
	Sex/Gender	61 (92%)
	Level of education	41 (62%)
	Occupation	39 (59%)
	Income level	30 (45%)
	Literacy	21 (32%)
	Urban/rural	19 (29%)
	Marital status	18 (27%)
	Distance from nearest health facility	13 (20%)
	Place of residence	11 (17%)
	Household size	11 (17%)
	Socioeconomic status	10 (15%)
	Race/Ethnicity	6 (9.1%)
	Health insurance status	5 (7.6%)
	Family structure	5 (7.6%)
	Religious status	4 (6.1%)
	Type of house	4 (6.1%)
	Patient health status/behavior	
	Type of illness	20 (30%)

Туре	Variable	$N = 66^{1}$
	Comorbidities	18 (27%)
	HIV status	18 (27%)
	Knowledge of disease	16 (24%)
	Symptoms experienced	15 (23%)
	Diabetes	15 (23%)
	Smoking status	14 (21%)
	Alcohol use	11 (17%)
	History of TB	9 (14%)
	Severity of illness	8 (12%)
	Type of TB (sputum smear positive/negative)	7 (11%)
	Heart disease, cardiovascular disease, or hypertension	7 (11%)
	Duration of symptoms	5 (7.6%)
	Lung disease	4 (6.1%)
	Asthma	4 (6.1%)
	Stigma experienced	4 (6.1%)
	Height/weight/BMI	4 (6.1%)
	Other drug use	3 (4.5%)
	Contact with person with TB	3 (4.5%)
	Patient journey data points	
	Number of visits	20 (30%)
	Type of provider for all instances of healthcare-seeking	15 (23%)
	Sector of facility for all instances of healthcare-seeking	17 (26%)
	Type of provider for initial healthcare-seeking visit	25 (38%)
	Sector of facility for initial healthcare-seeking visit	26 (39%)
	Type of provider for place of diagnosis	5 (7.6%)
	Sector of facility for place of diagnosis	8 (12%)
	Type of provider for place of treatment	6 (9.1%)
	Sector of facility for place of treatment	9 (14%)
	Reason for patient action (any)	18 (27%)
	Sought care for symptoms	6 (9.1%)
	Self-treated	4 (6.1%)
	Chest x-ray ordered	6 (9.1%)
	Hospitalized	2 (3.0%)
	Sector of facility for place of treatment	9 (14%)
	Availability of services	1 (1.5%)

383 Supplementary materials

384

385 Supplement 1 - Methodological Review Search Strategy

- 386
- 387 CINAHL
- 388 No field selected; Suggest subject terms checked
- 389 Total: 519 [6 Apr 29], update TB: 19, May 05
- 390

Data points	Key words
Patient journey	(TI ("Patient pathway analys*" OR PPA OR "treatment delay" OR "health- seeking" OR "healthcare-seeking" "health-seeking delay" OR "care seeking" OR "cascade of care" OR "access to care" OR "healthcare delivery" OR "diagnostic delay" OR "care seeking delay" OR "barriers and facilitators to care" OR "missed opportunit*" OR "care pathway*") OR AB ("Patient pathway analys*" OR PPA OR "treatment delay" OR "health-seeking" OR "health-seeking delay" OR "care seeking" OR "cascade of care" OR "access to care" OR "healthcare delivery" OR "diagnostic delay" OR "care seeking delay" OR "barriers and facilitators to care" OR "missed opportunit*" OR "care pathway*") OR (MH "Diagnosis, Delayed"))
Tuberculosis OR other pulmonary diseases OR selected infectious diseases	((MH "Tuberculosis, Pulmonary") OR TI (tb OR tuberculosis) OR AB(tb OR tuberculosis) OR (MH "Mycobacterium Tuberculosis")) OR (MH "respiratory tract diseases") OR (MH "respiratory disease) OR (MH "respiratory infection") OR (MH "malaria") OR TI (malaria OR HIV OR covid) OR AB (malaria OR HIV OR covid) OR (MH "human immunodeficiency virus") OR (MH "sars-cov-2") OR (MH "covid-19")

- 392 PubMed
- 393 Total: 1631 [1625 apr 29], update TB: 100 May 05
- Health seeking pathways (May 8):
- 395

Data points	Key words
Patient journey analysis	"Patient pathway analys*" [tw] OR PPA [tw] OR "treatment delay" [tw] OR "healthcare-seeking" [tw] OR "health-seeking delay" [tw] OR "care seeking" [tw] OR "cascade of care" [tw] OR "access to care" [tw] OR "healthcare delivery" [tw] OR "diagnostic delay" [tw] OR "pathway analysis" [tw] OR "care seeking delay" [tw] OR "barriers and facilitators to care" [tw] OR "missed opportunit*" [tw] OR "care pathway*" [tw] OR "delayed diagnosis" [MeSH] OR "critical pathways" [MeSH] OR "patient acceptance of health care"[MeSH]
Tuberculosis	Tuberculosis, Pulmonary [Mesh] OR tb[tw] OR tuberculosis[tw] OR Mycobacterium tuberculosis[Mesh]
Other pulmonary	"respiratory tract diseases"[MeSH Terms] OR "respiration

disorders"[MeSH Terms] OR respiratory disease[Text Word] OR "respiratory infection" OR "malaria"[MeSH Terms] OR malaria [tw] OR "hiv"[MeSH Terms] OR HIV[tw] OR "human immunodeficiency virus" [tw] "sars-cov-2"[MeSH Terms] OR "covid-19"[MeSH Terms] OR covid [tw]
OR covid [tw]

396

- 397 Web of Science
- 398 TS search; no filter
- 399 Total: 1336 (3518 apr 29), update TB: 58, May 05
- 400

Data points	Key words
Patient journry analysis	TS=("Patient pathway analys*" OR PPA OR "treatment delay" OR "healthcare-seeking" OR "health-seeking delay" OR "care seeking" OR "cascade of care" OR "access to care" OR "healthcare delivery" OR "diagnostic delay" OR "care seeking delay" OR "barriers and facilitators to care" OR "missed opportunit*" OR "care pathway*")
Tuberculosis	TS=(tb OR tuberculosis)
Other pulmonary diseases and relevant infectious disease	TS=("respiratory tract diseases" OR "respiration disorders" OR "respiratory disease" OR "respiratory infection" OR "malaria" OR OR HIV OR "human immunodeficiency virus" OR "sars-cov-2" OR "covid-19" OR covid)

401

- 402 Global Health via Ovid
- 403 Total: 932 (2798 apr 29), update TB: 100 May 05

404 No filter

405

Data points	Key words
Patient journey analysis	("Patient pathway analys*" OR PPA OR "treatment delay" OR "healthcare- seeking" OR "health-seeking delay" OR "care seeking" OR "cascade of care" OR "access to care" OR "healthcare delivery" OR "diagnostic delay" OR "care seeking delay" OR "barriers and facilitators to care" OR "missed opportunit*" OR "care pathway*").mp.
Tuberculosis	(tb OR tuberculosis).mp.
	("respiratory tract diseases" or "respiration disorders" or "respiratory disease" or "respiratory infection" or malaria or HIV or "human immunodeficiency virus" or "sars-cov-2" or covid-19 or covid).mp.

408 Supplement 2 - Data extraction form

409 General information

First author last name	[Open text field]
Year of publication	[Open text field]
Country/setting	[Open text field]
as specific as possible	
Disease type	[Open text field]
TB, HIV, malaria, etc.	
Study design/Data sources	[Open text field]
e.g. population-based surveys, patient	
interviews	
Quantitative/Qualitative/Mixed	[Open text field]
Total sample size	[Open text field]
Indicate sex of participants if available	

410

411 Patient healthcare-seeking journey data points included

i utent neutricure seeking journey uuu points metuueu	
Number of provider encounters to diagnosis	• Yes
Does the paper report the number of visits to a HC provider that it	○ No
took for patients to go from initial healthcare-seeking for their	• Unclear
symptoms until diagnosis? e.g. "On average, patients had 5	
encounters before being diagnosed"	
Type of provider for each encounter	• Yes
Does the paper mention which type of provider the patients saw?	○ No
(expressed as % of 1st encounter, 2nd encounter, etc.; or, number of	○ Unclear
patients who went to each type of provider)	
Sector of facility for each encounter	• Yes
Does the paper mention whether the providers are in the private	○ No
sector, public sector, or informal sector?	• Unclear
Proportions of patients per number of encounters to diagnosis	• Yes
For each number of encounters, do they say the proportion of	○ No
patients who had that many encounters between initial healthcare-	• Unclear
seeking and diagnosis? e.g. "20% of patients had 1-2 encounters,	
30% had 3 encounters"	
Time to diagnosis	• Yes
Do they give how long it took for patients to get diagnosed in time	○ No
increments (e.g. precise dates or time in days, weeks, months, etc.)?	• Unclear
Location/provider where diagnosis was made	• Yes
Do they say what type of health facility or provider the patients	○ No
received their diagnosis from?	• Unclear
Number of provider encounters to treatment	• Yes
Does the paper report the number of visits to a HC provider that it	○ No
took for patients to start treatment from the first provider encounter	• Unclear
or the point of diagnosis? e.g. "On average, patients had 5	
encounters between initial provider contact/diagnosis to receiving	
treatment"	
Time to treatment	• Yes
Do they give how long it took for patients to start treatment in time	○ No
increments (e.g. precise dates or time in days, weeks, months, etc.)?	○ Unclear

○ Yes
○ No
○ Unclear
• Yes
○ No
○ Unclear
• Yes
○ No
○ Unclear

412

413 Journey methodology & analysis

sourney methodology et unulysis	
Name or description of journey methodology (type of chart)	[Open text field]
e.g. Hansen-Chin, flowchart, Sankey chart, etc. Indicate if author's	
own methodology or replication of previous one. If author's own,	
indicate main components.	
Summary of analysis	[Open text field]
Description of statistical analysis	
Outcome variables or major themes	[Open text field]
Strengths	[Open text field]
If authors tried to limit recall bias, indicate how.	
Limitations	[Open text field]
Variables of interest or minor themes	[Open text field]
Indicate the specific outcome that the variable is in reference to	_
(cost, delay, access, etc.)	

414

415 Outcome measures

	1
Delays	□ Patient delay
Select all that apply	Provider delay
	□ Treatment delay
	Diagnostic delay
	□ Health system delay
	□ Total delay
	□ Delay, unspecified
	□ Other:
Journeys	□ Number of visits to diagnosis
Select all that apply	□ Number of visits to treatment
	□ Type of provider for every visit
	□ Sector of facility for every visit
	□ Type of provider for place of initial
	healthcare-seeking
	□ Sector of facility for place of initial

	 healthcare-seeking Type of provider for place of diagnosis Sector of facility for place of diagnosis Type of provider for place of treatment Sector of facility for place of treatment Other:
Other Methodology Variables Select all that apply	 Coverage of microscopy services among health facilities Access of microscopy at initial healthcare- seeking Coverage of treatment services among health facilities Access of treatment at initial healthcare- seeking Notification location Treatment outcome
<u>Time and date</u> Select all that apply	 Time to initial healthcare-seeking Time to diagnosis Time to treatment Date of first symptom Date of initial care-seeking Date of diagnosis Date of referral for treatment Date of treatment initiation Date of treatment completion Survival analysis (time to event/death) Other:
Costs of care (at any point in care) Select one	 Yes No Unclear
Other outcomes/major themes Select one	 One contract Yes No Unclear
Other, describe	[Open text field]

Other variables	
Patient characteristics	\Box Age
Select all that apply	□ Sex/Gender
	□ Race/Ethnicity
	□ Education level
	□ Literacy level
	□ Place of residence
	□ Urbanicity
	□ Income level
	□ Number of persons/children in household

F	
	 Socioeconomic status measure (e.g. material deprivation Distance from nearest health facility Marital status Smoking status Alcohol use Other drug use Comorbidities (any) Type of illness Severity of illness HIV status Diabetes status Cause of death Other:
Provider characteristics Select all that apply	 Age Sex/Gender Provider type Sector of facility Urbanicity Other:
<u>Healthcare/health system/healthcare-seeking</u> <u>characteristics</u> Select all that apply	 Costs of care Delay in accessing care Number of visits Type of provider of all instances of healthcare-seeking Sector of facility of all instances of healthcare-seeking Type of provider of initial care-seeking Sector of facility of initial care-seeking Type of provider of diagnosis Sector of facility of diagnosis Sector of facility of treatment location Sector of facility of services Region/Sub-national area Level of health facility Other:
If qualitative, major/minor themes	[Open text field]
Supplement 3 – Quality Assessment Electron General information Reviewer Initials	[Open text field]
Study ID	[Open text field]

Study Title	[Open text field]
First author last name	[Open text field]
Year of publication	[Open text field]
Type of Study	• Qualitative Research
Select one	• Mixed Methods
	 Analytical Cross-Sectional Study
	○ Cohort Study
	• Prevalence Study

424

425 Qualitative Research Quality Assessment

	•			•	•		
426	Source:	https://	jbi.glo	bal/si	tes/defa	ult/files/	2021-

- 427 10/Checklist_for_Qualitative_Research.docx
- 428

429 Discussion of critical appraisal criteria are added before each question for context.

Discussion of entitear appraisar enterna are added before each question	
1. Is there congruity between the stated philosophical	• Yes
perspective and the research methodology	○ No
	○ Unclear
Does the report clearly state the philosophical or theoretical	 Not applicable
premises on which the study is based? Does the report clearly state	
the methodological approach adopted on which the study is based?	
Is there congruence between the two? For example:	
A report may state that the study adopted a critical perspective and	
participatory action research methodology was followed. Here there	
is congruence between a critical view (focusing on knowledge	
arising out of critique, action and reflection) and action research (an	
approach that focuses on firstly working with groups to reflect on	
issues or practices, then considering how they could be different;	
then acting to create a change; and finally identifying new	
knowledge arising out of the action taken). However, a report may	
state that the study adopted an interpretive perspective and used	
survey methodology. Here there is incongruence between an	
interpretive view (focusing on knowledge arising out of studying	
what phenomena mean to individuals or groups) and surveys (an	
approach that focuses on asking standard questions to a defined	
study population); a report may state that the study was qualitative	
or used qualitative methodology (such statements do not	
demonstrate rigour in design) or make no statement on philosophical	
orientation or methodology.	
2. Is there congruity between the research methodology and the	○ Yes
research question or objectives?	○ No
Is the study methodology appropriate for addressing the research	○ Unclear
question? For example:	○ Not applicable
A report may state that the research question was to seek	
understandings of the meaning of pain in a group of people with	
understandings of the meaning of pair in a group of people with	

· · · · · · · · · · · · · · · · · · ·	
 rheumatoid arthritis and that a phenomenological approach was taken. Here, there is congruity between this question and the methodology. A report may state that the research question was to establish the effects of counselling on the severity of pain experience and that an ethnographic approach was pursued. A question that tries to establish cause-and effect cannot be addressed by using an ethnographic approach (as ethnography sets out to develop understandings of cultural practices) and thus, this would be incongruent. 3. Is there congruity between the research methodology and the methods used to collect data 	○ Yes ○ No
Are the data collection methods appropriate to the methodology? For example:	 Ounclear Not applicable
A report may state that the study pursued a phenomenological approach and data was collected through phenomenological interviews. There is congruence between the methodology and data collection; a report may state that the study pursued a phenomenological approach and data was collected through a postal questionnaire. There is incongruence between the methodology and data collection here as phenomenology seeks to elicit rich descriptions of the experience of a phenomena that cannot be achieved through seeking written responses to standardized questions.	
4. Is there congruity between the research methodology and the	○ Yes
representation and analysis of data? Are the data analyzed and represented in ways that are congruent with the stated methodological position? For example:	○ No○ Unclear○ Not applicable
A report may state that the study pursued a phenomenological approach to explore people's experience of grief by asking participants to describe their experiences of grief. If the text generated from asking these questions is searched to establish the meaning of grief to participants, and the meanings of all participants are included in the report findings, then this represents congruity; the same report may, however, focus only on those meanings that were common to all participants and discard single reported meanings. This would not be appropriate in phenomenological work.	
5. Is there congruence between the research methodology and the interpretation of results? Are the results interpreted in ways that are appropriate to the methodology? For example:	 Yes No Unclear Not applicable
A report may state that the study pursued a phenomenological approach to explore people's experience of facial disfigurement and	

the results are used to inform practitioners about accommodating individual differences in care. There is congruence between the methodology and this approach to interpretation; a report may state that the study pursued a phenomenological approach to explore people's experience of facial disfigurement and the results are used to generate practice checklists for assessment. There is incongruence between the methodology and this approach to interpretation as phenomenology seeks to understand the meaning of a phenomenon for the study participants and cannot be interpreted to suggest that this can be generalized to total populations to a degree where standardized assessments will have relevance across a population. 6. Is there a statement locating the researcher culturally or theoretically?	 ○ Yes ○ No
theoretically? Are the beliefs and values, and their potential influence on the study declared? For example:	 ○ No ○ Unclear ○ Not applicable
The researcher plays a substantial role in the qualitative research process and it is important, in appraising evidence that is generated in this way, to know the researcher's cultural and theoretical orientation. A high quality report will include a statement that clarifies this.	
7. Is the influence of the researcher on the research, and vice-versa, addressed?Is the potential for the researcher to influence the study and for the potential of the research process itself to influence the researcher and her/his interpretations acknowledged and addressed? For example:	 ○ Yes ○ No ○ Unclear ○ Not applicable
Is the relationship between the researcher and the study participants addressed? Does the researcher critically examine her/his own role and potential influence during data collection? Is it reported how the researcher responded to events that arose during the study?	
8. Are participants, and their voices, adequately represented? Generally, reports should provide illustrations from the data to show the basis of their conclusions and to ensure that participants are represented in the report.	 Yes No Unclear Not applicable
 9. Is the research ethical according to current criteria or, for recent studies, and is there evidence of ethical approval by an appropriate body? A statement on the ethical approval process followed should be in the report. 	 ○ Yes ○ No ○ Unclear ○ Not applicable
10. Do the conclusions drawn in the research report flow from the analysis, or interpretation, of the data? This criterion concerns the relationship between the findings reported and the views or words of study participants. In appraising	 ○ Yes ○ No ○ Unclear ○ Not applicable

a paper, appraisers seek to satisfy themselves that the conclusions drawn by the research are based on the data collected; data being the text generated through observation, interviews or other processes.	
Overall appraisal	 Low quality Medium quality High quality Seek further info
Comments	[Open text field]

430

431 Mixed Methods Quality Assessment

- 432 Adapted from the Mixed Methods Appraisal Tool. Citation: Hong QN, Pluye P, Fabregues S,
- 433 Bartlett G, Boardman F, Cargo M, Dagenais P, Gagnon M-P, Griffiths F, Nicolau B,
- 434 O'Cathain A, Rousseau M-C, Vedel I. Mixed Methods Appraisal Tool (MMAT), version
- 435 2018. Registration of Copyright (#1148552), Canadian Intellectual Property Office, Industry
- 436 Canada.

1. Are there clear research questions?	○ Yes
1. Are there clear research questions?	
	○ No
	• Unclear
	• Not applicable
2. Do the collected data allow the research questions to be	• Yes
addressed?	\circ No
	○ Unclear
	\circ Not applicable
Part 1: Assessment of the Qualitative Aspects of the Study	
Is the qualitative approach appropriate to answer the research	• Yes
question?	○ No
d	○ Unclear
	• Not applicable
Are the qualitative data collection methods adequate to address the	• Yes
research question?	○ No
	○ Unclear
	• Not applicable
Are the findings adequately derived from the data?	○ Yes
	○ No
	○ Unclear
	• Not applicable
Is the interpretation of results sufficiently substantiated by data?	• Yes
	○ No
	○ Unclear
	• Not applicable
Is there coherence between qualitative data sources, collection,	• Yes
analysis, and interpretation?	○ No
	• Unclear
	• Not applicable
Part 2: Assessment of the Quantitative Aspects of the Study	TT
Is the sampling strategy relevant to address the research question?	• Yes
is the sampling strategy relevant to address the research question?	○ Tes ○ No
	○ Unclear

SolutionSolutionIs the sample representative of the target population?SolutionSolutionNoSolutionUnclearSolutionNot applicableAre the measurements appropriate?YesSolution
In the mapped problem is the magnet propriate of the magnet propriate propriate of the magnet propriate proprise propriate propriate proprise
OunclearAre the measurements appropriate?• YesNo• UnclearNo• UnclearNot applicable• Not applicableIs the risk of nonresponse bias low?• YesNo• UnclearNo• UnclearNo• UnclearNo• UnclearNo• UnclearNo• UnclearNo• UnclearNot applicable• Not applicableIs the statistical analysis appropriate to answer the research question?• YesNo• UnclearNo• Unclear• No• Unclear• Not applicable• Not applicable• Is there an adequate rationale for using a mixed methods design to• Yes
Are the measurements appropriate?O Not applicableAre the measurements appropriate?O YesO NoUnclearO Not applicableNot applicableIs the risk of nonresponse bias low?O YesO NoUnclearO NoUnclearO NoUnclearO NoUnclearO Not applicableNot applicableIs the statistical analysis appropriate to answer the research question?YesO NoUnclearO NoUnclearO NoUnclearO NoUnclearIs there an adequate rationale for using a mixed methods design toYes
Are the measurements appropriate? Yes No Unclear Not applicable Is the risk of nonresponse bias low? Yes No Unclear No Unclear No Unclear No Unclear No Unclear No Unclear Not applicable Is the statistical analysis appropriate to answer the research question? Sthe statistical analysis appropriate to answer the research on the Mixed Methods Aspects of the Study Is there an adequate rationale for using a mixed methods design to Yes Yes Yes
 No Unclear Not applicable Is the risk of nonresponse bias low? Yes No Unclear No Unclear Not applicable Is the statistical analysis appropriate to answer the research question? Yes No Unclear Not applicable Yes No Unclear Not applicable
• Unclear • Not applicableIs the risk of nonresponse bias low?• Yes • No • Unclear • No • Unclear • Not applicableIs the statistical analysis appropriate to answer the research question?• Yes • No • Unclear • Not applicable• Part 3: Assessment of the Mixed Methods Aspects of the Study• Yes
S the risk of nonresponse bias low?O YesS the risk of nonresponse bias low?O YesS the statistical analysis appropriate to answer the research question?O YesS the statistical analysis appropriate to answer the research O Not applicableO YesIs the statistical analysis appropriate to answer the research O Not applicableO YesPart 3: Assessment of the Mixed Methods Aspects of the StudyO YesIs there an adequate rationale for using a mixed methods design toO Yes
Is the risk of nonresponse bias low? • Yes Is the risk of nonresponse bias low? • No • No • Unclear • Not applicable • Yes Is the statistical analysis appropriate to answer the research question? • Yes • No • Unclear • Not applicable • Not applicable Part 3: Assessment of the Mixed Methods Aspects of the Study • Yes Is there an adequate rationale for using a mixed methods design to • Yes
• No • Unclear • Not applicable Is the statistical analysis appropriate to answer the research question? • Yes • No • Unclear • Not applicable Part 3: Assessment of the Mixed Methods Aspects of the Study Is there an adequate rationale for using a mixed methods design to • Yes
• Unclear • Not applicable Is the statistical analysis appropriate to answer the research question? • Yes • No • Unclear • No • Unclear • No • Unclear • Not applicable • Not applicable Part 3: Assessment of the Mixed Methods Aspects of the Study • Yes Is there an adequate rationale for using a mixed methods design to • Yes
Is the statistical analysis appropriate to answer the research question?• Not applicableONO• VesONO• Unclear• Not applicable• Not applicablePart 3: Assessment of the Mixed Methods Aspects of the Study• YesIs there an adequate rationale for using a mixed methods design to• Yes
Is the statistical analysis appropriate to answer the research question? • Yes o No • Unclear o Not applicable • Not applicable Part 3: Assessment of the Mixed Methods Aspects of the Study • Yes Is there an adequate rationale for using a mixed methods design to • Yes
question? No Unclear Not applicable Part 3: Assessment of the Mixed Methods Aspects of the Study S there an adequate rationale for using a mixed methods design to Yes
• Unclear • Not applicable Part 3: Assessment of the Mixed Methods Aspects of the Study Is there an adequate rationale for using a mixed methods design to • Yes
O Not applicable Part 3: Assessment of the Mixed Methods Aspects of the Study Is there an adequate rationale for using a mixed methods design to O Not applicable
Part 3: Assessment of the Mixed Methods Aspects of the StudyIs there an adequate rationale for using a mixed methods design to• Yes
Is there an adequate rationale for using a mixed methods design to • Yes
address the research question?
address the research question? • No • Unclear
• Not applicable
Are the different components of the study effectively integrated to \circ Yes
answer the research question?
• The research question : • The • • The • • • • • • • • • • • • • • • • • • •
• Not applicable
Are the outputs of the integration of qualitative and quantitative • Yes
components adequately interpreted?
• The other
• Not applicable
Are divergences and inconsistencies between quantitative and • Yes
qualitative results adequately addressed? • No
• Unclear
• Not applicable
Do the different components of the study adhere to the quality • Yes
criteria of each tradition of the methods involved?
• Unclear
• Not applicable
Overall appraisal • Low quality
• Medium quality
• High quality
• Seek further info
Comments [Open text field]

437

438 Analytical Cross-Sectional Quality Assessment

439 Source: <u>https://jbi.global/sites/default/files/2021-</u>

440 <u>10/Checklist_for_Analytical_Cross_Sectional_Studies.docx</u>

Discussion of critical appraisal criteria are added before each question 1. Were the criteria for inclusion in the sample clearly defined ?	• Yes
The authors should provide clear inclusion and exclusion criteria	○ No
that they developed prior to recruitment of the study participants.	• Unclear
The inclusion/exclusion criteria should be specified (e.g., risk, stage	• Not applicable
of disease progression) with sufficient detail and all the necessary	- itter application
information critical to the study.	
2. Were the study subjects and the setting described in detail?	• Yes
The study sample should be described in sufficient detail so that	○ No
other researchers can determine if it is comparable to the population	• Unclear
of interest to them. The authors should provide a clear description of	 Not applicable
the population from which the study participants were selected or	
recruited, including demographics, location, and time period.	
3. Was the exposure measured in a valid and reliable way?	• Yes
The study should clearly describe the method of measurement of	○ No
exposure. Assessing validity requires that a 'gold standard' is	• Unclear
available to which the measure can be compared. The validity of	 Onclean Not applicable
exposure measurement usually relates to whether a current measure	
is appropriate or whether a measure of past exposure is needed.	
is appropriate of whether a measure of past exposure is needed.	
Reliability refers to the processes included in an epidemiological	
study to check repeatability of measurements of the exposures.	
These usually include intra-observer reliability and inter-observer	
reliability.	
4. Were objective, standard criteria used for measurement of	• Yes
the condition?	○ No
It is useful to determine if patients were included in the study based	• Unclear
on either a specified diagnosis or definition. This is more likely to	• Not applicable
decrease the risk of bias. Characteristics are another useful approach	
to matching groups, and studies that did not use specified diagnostic	
methods or definitions should provide evidence on matching by key	
characteristics.	
5. Were confounding factors identified?	• Yes
Confounding has occurred where the estimated intervention	○ No
exposure effect is biased by the presence of some difference	• Unclear
between the comparison groups (apart from the exposure	• Not applicable
investigated/of interest). Typical confounders include baseline	11
characteristics, prognostic factors, or concomitant exposures (e.g.	
smoking). A confounder is a difference between the comparison	
groups and it influences the direction of the study results. A high	
quality study at the level of cohort design will identify the potential	
confounders and measure them (where possible). This is difficult for	
studies where behavioural, attitudinal or lifestyle factors may impact	
on the results.	
6. Were strategies to deal with confounding factors stated?	• Yes
	○ No
Strategies to deal with effects of confounding factors may be dealt	
Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or	 Unclear
Strategies to deal with effects of confounding factors may be dealt within the study design or in data analysis. By matching or stratifying sampling of participants, effects of confounding factors	 Unclear Not applicable

assess the statistics used in the study. Most will be some form of multivariate regression analysis to account for the confounding factors measured.	
7. Were the outcomes measured in a valid and reliable way? Read the methods section of the paper. If for e.g. lung cancer is assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If lung cancer is assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.	 ○ Yes ○ No ○ Unclear ○ Not applicable
Having established the objectivity of the outcome measurement (e.g. lung cancer) instrument, it's important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? (e.g. radiographers). If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised?	
8. Was appropriate statistical analysis used? As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.	 ○ Yes ○ No ○ Unclear ○ Not applicable
For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.	
Overall appraisal	 Low quality Medium quality High quality Seek further info
Comments	[Open text field]

Cohort Study Quality Assessment

446 Source: <u>https://jbi.global/sites/default/files/2021-10/Checklist_for_Cohort_Studies.docx</u>

448 Discussion of critical appraisal criteria are added before each question for context.

1. Were the two groups similar and recruited from the same population?	○ Yes○ No
Check the paper carefully for descriptions of participants to	• Unclear
determine if patients within and across groups have similar	• Not applicable
characteristics in relation to exposure (e.g. risk factor under	
investigation). The two groups selected for comparison should be as	
similar as possible in all characteristics except for their exposure	
status, relevant to the study in question. The authors should provide	
clear inclusion and exclusion criteria that they developed prior to recruitment of the study participants.	
2. Were the exposures measured similarly to assign people to	• Yes
both exposed and unexposed groups?	○ Yes ○ No
A high-quality study at the level of cohort design should mention or	• Unclear
describe how the exposures were measured. The exposure measures	• Not applicable
should be clearly defined and described in detail. This will enable	TT TT
reviewers to assess whether or not the participants received the	
exposure of interest.	
3. Was the exposure measured in a valid and reliable way?	• Yes
The study should clearly describe the method of measurement of	○ No
exposure. Assessing validity requires that a 'gold standard' is	• Unclear
available to which the measure can be compared. The validity of	• Not applicable
exposure measurement usually relates to whether a current measure	
is appropriate or whether a measure of past exposure is needed.	
Reliability refers to the processes included in an epidemiological study to check repeatability of measurements of the exposures. These usually include intra-observer reliability and inter-observer reliability.	
4. Were confounding factors identified?	• Yes
Confounding has occurred where the estimated intervention	○ No
exposure effect is biased by the presence of some difference	• Unclear
between the comparison groups (apart from the exposure	 Not applicable
investigated/of interest). Typical confounders include baseline	
characteristics, prognostic factors, or concomitant exposures (e.g.	
smoking). A confounder is a difference between the comparison	
groups and it influences the direction of the study results. A high	
quality study at the level of cohort design will identify the potential	
confounders and measure them (where possible). This is difficult for studies where behavioral, attitudinal or lifectule factors may impact	
studies where behavioral, attitudinal or lifestyle factors may impact on the results.	
5. Were strategies to deal with confounding factors stated?	○ Yes
Strategies to deal with effects of confounding factors may be dealt	○ Tes ○ No
within the study design or in data analysis. By matching or	• Unclear
stratifying sampling of participants, effects of confounding factors	 Not applicable
can be adjusted for. When dealing with adjustment in data analysis,	Tritude
assess the statistics used in the study. Most will be some form of	
multivariate regression analysis to account for the confounding	
factors measured. Look out for a description of statistical methods as	
regression methods such as logistic regression are usually employed	

to deal with confounding factors/variables of interest.	
6. Were the groups/participants free of the outcome at the start	• Yes
of the study (or at the moment of exposure)?	○ No
The participants should be free of the outcomes of interest at the	○ Unclear
start of the study. Refer to the 'methods' section in the paper for this	• Not applicable
information, which is usually found in descriptions of	
participant/sample recruitment, definitions of variables, and/or	
inclusion/exclusion criteria.	
7. Were the outcomes measured in a valid and reliable way?	• Yes
Read the methods section of the paper. If for e.g. lung cancer is	○ No
assessed based on existing definitions or diagnostic criteria, then the	• Unclear
answer to this question is likely to be yes. If lung cancer is assessed	 Not applicable
using observer reported, or self-reported scales, the risk of over- or	
under-reporting is increased, and objectivity is compromised.	
Importantly, determine if the measurement tools used were validated	
instruments as this has a significant impact on outcome assessment	
validity.	
Having established the objectivity of the outcome measurement (e.g.	
lung cancer) instrument, it's important to establish how the	
measurement was conducted. Were those involved in collecting data	
trained or educated in the use of the instrument/s? (e.g.	
radiographers). If there was more than one data collector, were they	
similar in terms of level of education, clinical or research	
experience, or level of responsibility in the piece of research being	
appraised?	
8. Was the follow up time reported and sufficient to be long	• Yes
enough for outcomes to occur?	○ No
The appropriate length of time for follow up will vary with the	• Unclear
nature and characteristics of the population of interest and/or the	• Not applicable
intervention, disease or exposure. To estimate an appropriate	11
duration of follow up, read across multiple papers and take note of	
the range for duration of follow up. The opinions of experts in	
clinical practice or clinical research may also assist in determining	
an appropriate duration of follow up. For example, a longer	
timeframe may be needed to examine the association between	
occupational exposure to asbestos and the risk of lung cancer. It is	
important, particularly in cohort studies that follow up is long	
enough to enable the outcomes. However, it should be remembered	
that the research question and outcomes being examined would	
probably dictate the follow up time.	o Vee
9. Was follow up complete, and if not, were the reasons to loss to follow up described and employed?	• Yes
follow up described and explored?	○ No
It is important in a cohort study that a greater percentage of people	• Unclear
are followed up. As a general guideline, at least 80% of patients	• Not applicable
should be followed up. Generally a dropout rate of 5% or less is	
considered insignificant. A rate of 20% or greater is considered to	
significantly impact on the validity of the study. However, in	
observational studies conducted over a lengthy period of time a	1

Comments	[Open text field]
Overall appraisal	 Low quality Medium quality High quality Seek further info
For studies utilizing regression analysis, it is useful to identify if the study identified which variables were included and how they related to the outcome. If stratification was the analytical approach used, were the strata of analysis defined by the specified variables? Additionally, it is also important to assess the appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond.	
11. Was appropriate statistical analysis used? As with any consideration of statistical analysis, consideration should be given to whether there was a more appropriate alternate statistical method that could have been used. The methods section of cohort studies should be detailed enough for reviewers to identify which analytical techniques were used (in particular, regression or stratification) and how specific confounders were measured.	 Yes No Unclear Not applicable
Therefore, participants with unequal follow up periods must be taken into account in the analysis, which should be adjusted to allow for differences in length of follow up periods. This is usually done by calculating rates which use person-years at risk, i.e. considering time in the denominator.	
10. Were strategies to address incomplete follow up utilized? Some people may withdraw due to change in employment or some may die; however, it is important that their outcomes are assessed. Selection bias may occur as a result of incomplete follow up.	 Yes No Unclear Not applicable
Reporting of efforts to follow up participants that dropped out may be regarded as an indicator of a well conducted study. Look for clear and justifiable description of why people were left out, excluded, dropped out etc. If there is no clear description or a statement in this regards, this will be a 'No'.	
higher dropout rate is to be expected. A decision on whether to include or exclude a study because of a high dropout rate is a matter of judgement based on the reasons why people dropped out, and whether dropout rates were comparable in the exposed and unexposed groups.	

449

450 **Prevalence Study Quality Assessment**

- 451 Source: <u>https://jbi.global/sites/default/files/2021-10/Checklist_for_Prevalence_Studies.docx</u>
- 452

453 Discussion of critical appraisal criteria are added before each question for context.

1. Was the sample frame appropriate to address the target	○ Yes
population?	• No

This question relies upon knowledge of the broader	• Unclear
characteristics of the population of interest and the geographical	 Not applicable
area. If the study is of women with breast cancer, knowledge of at	
least the characteristics, demographics and medical history is	
needed. The term "target population" should not be taken to infer	
every individual from everywhere or with similar disease or	
exposure characteristics. Instead, give consideration to specific	
population characteristics in the study, including age range, gender,	
morbidities, medications, and other potentially influential factors.	
For example, a sample frame may not be appropriate to address the	
target population if a certain group has been used (such as those	
working for one organisation, or one profession) and the results then	
inferred to the target population (i.e. working adults). A sample	
frame may be appropriate when it includes almost all the members	
of the target population (i.e. a census, or a complete list of	
participants or complete registry data).	
	.
2. Were study participants recruited in an appropriate way?	○ Yes
Studies may report random sampling from a population, and the	○ No
methods section should report how sampling was performed.	○ Unclear
Random probabilistic sampling from a defined subset of the	 Not applicable
population (sample frame) should be employed in most cases,	
however, random probabilistic sampling is not needed when	
everyone in the sampling frame will be included/analysed. For	
example, reporting on all the data from a good census is appropriate	
as a good census will identify everybody. When using cluster	
sampling, such as a random sample of villages within a region, the	
methods need to be clearly stated as the precision of the final	
prevalence estimate incorporates the clustering effect. Convenience	
samples, such as a street survey or interviewing lots of people at a	
public gatherings are not considered to provide a representative	
sample of the base population.	
sample of the base population.	
3. Was the sample size adequate?	○ Yes
The larger the sample, the narrower will be the confidence interval	○ No
•	• Unclear
around the prevalence estimate, making the results more precise. An	
adequate sample size is important to ensure good precision of the	○ Not applicable
final estimate. Ideally we are looking for evidence that the authors	
conducted a sample size calculation to determine an adequate	
sample size. This will estimate how many subjects are needed to	
produce a reliable estimate of the measure(s) of interest. For	
conditions with a low prevalence, a larger sample size is needed.	
Also consider sample sizes for subgroup (or characteristics)	
analyses, and whether these are appropriate. Sometimes, the study	
will be large enough (as in large national surveys) whereby a sample	
size calculation is not required. In these cases, sample size can be	
considered adequate. When there is no sample size calculation and it	
is not a large national survey, the reviewers may consider	
conducting their own sample size analysis.	
conducting then own sumple size analysis.	1

4. Were the study subjects and setting described in detail? Certain diseases or conditions vary in prevalence across different geographic regions and populations (e.g. Women vs. Men, sociodemographic variables between countries). The study sample should be described in sufficient detail so that other researchers can determine if it is comparable to the population of interest to them.	 Yes No Unclear Not applicable
5. Was data analysis conducted with sufficient coverage of the identified sample? Coverage bias can occur when not all subgroups of the identified sample respond at the same rate. For instance, you may have a very high response rate overall for your study, but the response rate for a certain subgroup (i.e. older adults) may be quite low.	 Yes No Unclear Not applicable
6. Were valid methods used for the identification of the condition? Here we are looking for measurement or classification bias. Many health problems are not easily diagnosed or defined and some measures may not be capable of including or excluding appropriate levels or stages of the health problem. If the outcomes were assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If the outcomes were assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.	 Yes No Unclear Not applicable
7. Was the condition measured in a standard, reliable way for all participants? Considerable judgment is required to determine the presence of some health outcomes. Having established the validity of the outcome measurement instrument (see item 6 of this scale), it is important to establish how the measurement was conducted. Were those involved in collecting data trained or educated in the use of the instrument/s? If there was more than one data collector, were they similar in terms of level of education, clinical or research experience, or level of responsibility in the piece of research being appraised? When there was more than one observer or collector, was there comparison of results from across the observers? Was the condition measured in the same way for all participants?	 Yes No Unclear Not applicable
8. Was there appropriate statistical analysis? Importantly, the numerator and denominator should be clearly reported, and percentages should be given with confidence intervals. The methods section should be detailed enough for reviewers to identify the analytical technique used and how specific variables were measured. Additionally, it is also important to assess the	 Yes No Unclear Not applicable

appropriateness of the analytical strategy in terms of the assumptions associated with the approach as differing methods of analysis are based on differing assumptions about the data and how it will respond. 9. Was the response rate adequate, and if not, was the low response rate managed appropriately? A large number of dropouts, refusals or "not founds" amongst selected subjects may diminish a study's validity, as can a low response rates for survey studies. The authors should clearly discuss the response rate and any reasons for non-response and compare persons in the study to those not in the study, particularly with regards to their socio-demographic characteristics. If reasons for non-response appear to be unrelated to the outcome measured and the characteristics of non-responders are comparable to those who do respond in the study (addressed in question 5, coverage bias), the researchers may be able to justify a more modest response rate.	 ○ Yes ○ No ○ Unclear ○ Not applicable
Overall appraisal	 ○ Low quality ○ Medium quality
	High qualitySeek further info
Comments	[Open text field]

454 455 456

457 Supplement 4 – Quality Appraisal

S/No	Study Title	First author last name	Year of publication	Type of Study	Overall appraisal
				Analytical	
	Health care seeking behavior and patient			Cross-	High
1	delay in tuberculosis diagnosis	Almeida	2015	Sectional	
	The road to tuberculosis treatment in rural				
•	Nepal: A qualitative assessment of 26				High
2	journeys	Asbroek	2008	Qualitative	
	Delays to anti-tuberculosis treatment				
	intiation among cases on directly observed treatment short course in districts of			Analytical	Lliab
				Analytical Cross-	High
3	southwestern Ethiopia: a cross sectional	Asres	2019	Sectional	
3	study Such a long journey: What health seeking	ASIES	2019	Sectional	
	pathways of patients with drug resistant				High
4	tuberculosis in Mumbai tell us	Bhattacharya	2019	Qualitative	riigii
т	How do patients access the private sector in	Bronner Murrison	2019	Cross-Sectional	High
	Chennai, India? An evaluation of delays in	bronner warnson	2010	Study	ingi
5	tuberculosis diagnosis			Study	
5	Health-seeking behaviour and treatment				
	delay in patients with pulmonary			Analytical	
	tuberculosis in Switzerland: some slip			Cross-	High
6	through the net	Christian	2018	Sectional	
•	Delays in TB Diagnosis and Treatment			Analytical	
	Initiation in Burkina Faso during the			Cross-	High
7	COVID-19 Pandemic	Diallo	2022	Sectional	3
	Health seeking behaviour and delayed			Analytical	
	management of tuberculosis patients in			Cross-	High
8	rural Bangladesh	Ehsanul Huq	2018	Sectional	-
	Real-world colorectal cancer diagnostic			Analytical	High
9	pathways in Ontario, Canada: A	Guan	2022	Cross-	riigii

	population-based study			Sectional	
10	Patient pathways of tuberculosis care- seeking and treatment: an individual- level analysis of National Health Insurance data in Taiwan	Ku	2020	Cohort	High
11	Health-seeking behaviour for febrile illness in malaria-endemic Kolasib district, Mizoram, India	Lalchhuanawma	2012	Analytical Cross- Sectional	High
12	Patient pathways and delays to diagnosis and treatment of tuberculosis in an urban setting in Indonesia	Lestari	2020	Analytical Cross- Sectional	High
13	Health-seeking pathway and factors leading to delays in tuberculosis diagnosis in West Pokot County, Kenya: a grounded theory study	Mbuthia	2018	Qualitative	High
14	Delayed consultation among pulmonary tuberculosis patients: a cross sectional study of 10 DOTS districts of Ethiopia	Mesfin	2009	Analytical Cross- Sectional	High
15	Patterns and predictors of malaria care- seeking, diagnostic testing, and artemisinin-based combination therapy for children under five with fever in Northern Nigeria: a cross-sectional study	Millar	2014	Analytical Cross- Sectional	High
16	Demand for malaria rapid diagnostic test, health care-seeking behaviour, and drug use among rural community members with fever or malaria-like illness in Ebonyi state, Nigeria: a cross-sectional household survey	Omale	2021	Analytical Cross- Sectional	High
17	Care-seeking during fatal childhood illness in rural South Africa: a qualitative study	Price	2021	Qualitative	High
18	Effect of public-private interface agency in	Shah	2020	Analytical	High

	Patna and Mumbai, India: Does it alter			Cross-	
	durations and delays in care seeking for			Sectional	
	drug-sensitive pulmonary tuberculosis?			Occional	
	Healthcare-seeking behavior, treatment				
	delays and its determinants among			Analytical	
	pulmonary tuberculosis patients in rural			Cross-	High
19	Nigeria: a cross-sectional study	Ukwaja	2013	Sectional	
13	Tuberculosis patients' knowledge and	Okwaja	2013	Sectional	
	beliefs about tuberculosis: a mixed				
	methods study from the Pacific Island				High
20	nation of Vanuatu	Viney	2014	Mixed Methods	
20	Comparing patient care seeking pathways	Viney	2014	Analytical	
	in three models of hospital and TB			Cross-	High
21	programme collaboration in China	Wei	2013	Sectional	riigii
21	Transaction costs of access to health care:		2013	Occilonal	
	Implications of the care-seeking pathways				
	of tuberculosis patients for health system				
	governance in Nigeria			Cross-	
22		Abimbola	2015	Sectional Study	Medium
	Diagnostic delay amongst tuberculosis		2010	Coolional Cludy	moaiain
	patients in Jogjakarta Province, Indonesia				
	is related to the quality of services in			Cross-	
23	DOTS facilities	Ahmad	2011	Sectional Study	Medium
	Knowledge on the transmission,				
	prevention and treatment of malaria				
	1				
	among two endemic populations of			Cross-	
24	among two endemic populations of Bangladesh and their health-seeking	Ahmed	2009	Cross- Sectional Study	Medium
24	among two endemic populations of Bangladesh and their health-seeking behaviour	Ahmed	2009	Cross- Sectional Study	Medium
24	among two endemic populations of Bangladesh and their health-seeking behaviour Duration of intervals in the care seeking	Ahmed	2009		Medium
24	among two endemic populations of Bangladesh and their health-seeking behaviour	Ahmed	2009		Medium

	Patient's site of first access to health	1			
				Cross	
26	system influences length of delay for	A.v.o	2010	Cross-	Medium
20	tuberculosis treatment in Tajikistan	Aye	2010	Sectional Study	wealum
	Care seeking and attitudes towards				
	treatment compliance by newly enrolled				
	tuberculosis patients in the district			Qualitative	
07	treatment programme in rural western	Avioi	2011		Medium
27	Kenya: a qualitative study	Ayisi	2011	Research	wealum
	Men with sexually transmitted diseases in			Cross	
20	Bangkok: where do they go for treatment	Denierottenenern	1007	Cross-	Madium
28	and why?	Benjarattanaporn	1997	Sectional Study	Medium
	Pre-treatment delay and out of pocket			Cross	
20	expenses by notified new tuberculosis	Chadha	2022	Cross-	Madium
29	patients in an Indian mega city	Chadha	2022	Sectional Study	Medium
	Care Seeking Behavior of Chest				
	Symptomatics: A Community Based Study			0	
00	Done in South India after the		0040	Cross-	
30	Implementation of the RNTCP	Charles	2010	Sectional Study	Medium
	Cost of seeking care for tuberculosis since			•	
	the implementation of universal health			Cross-	
31	coverage in Indonesia	Fuady	2020	Sectional Study	Medium
	Care seeking behaviour and various				
~~	delays in tuberculosis patients registered		00/0	Cross-	
32	under RNTCP in Pune city	Gothankar	2016	Sectional Study	Medium
	The relationship between poverty and				
	healthcare seeking among patients				
	hospitalized with acute febrile illnesses in			Cross-	
33	Chittagong, Bangladesh	Herdman	2016	Sectional Study	Medium
	Healthcare Seeking and Access to Care				
	for Pneumonia, Sepsis, Meningitis, and			Cross-	
34	Malaria in Rural Gambia	Hossain	2022	Sectional Study	Medium
35	Barriers on the pathway to survival for	Kallander	2019	Cross-	Medium

	a bildram, ab da a factor tara sta bila illa secondo da	İ			
	children dying from treatable illnesses in			Sectional Study	
	Inhambane province, Mozambique				
	Study of factors leading to treatment delay				
	in new sputum positive pulmonary				
	tuberculosis patients and its impact on				
36	sputum conversion	Kumawat	2022	Cohort Study	Medium
	Patients are paying too much for				
	tuberculosis: a direct cost-burden			Cross-	
37	evaluation in Burkina Faso	Laokri	2013	Sectional Study	Medium
	Case-finding tuberculosis patients:				
	diagnostic and treatment delays and their			Cross-	
38	determinants	Maamari	2008	Sectional Study	Medium
	How much do delayed healthcare seeking,				
	delayed care provision, and diversion from				
	primary care contribute to the transmission			Cross-	
39	of STIs?	Mercer	2007	Sectional Study	Medium
	Pulmonary tuberculosis in Patna, India:				
	Durations, delays, and health care seeking				
	behaviour among patients identified			Cross-	
40	through household surveys	Mistry	2017	Sectional Study	Medium
	Durations and Delays in Care Seeking,				
	Diagnosis and Treatment Initiation in				
	Uncomplicated Pulmonary Tuberculosis				
41	Patients in Mumbai, India	Mistry	2016	Mixed Methods	Medium
	Patient navigation pathway and barriers to				
	treatment seeking in cancer in India: A				
42	qualitative inquiry	Pati	2013	Mixed Methods	Medium
	Care-seeking pathways, care challenges,				
	and coping experiences of rural women				
	living with rheumatoid arthritis in Odisha,			Qualitative	
43	India	Pati	2019	Research	Medium
44	Factors associated with patient and health	Rajeswari	2002	Cross-	Medium

	system delays in the diagnosis of			Sectional Study	
	tuberculosis in South India			Sectional Study	
	Patient treatment pathways of multidrug-				
	resistant tuberculosis cases in coastal				
	South India: Road to a drug resistant			Cross-	
45	tuberculosis center	Rathi	2021	Sectional Study	Medium
	Care seeking behaviour and diagnostic				
	processes in patients with smear-positive			Cross-	
46	pulmonary tuberculosis in Malawi	Salaniponi	2000	Sectional Study	Medium
	A comparison of patient treatment	·		,	
	pathways among multidrug-resistant and				
	drug-sensitive TB cases in Delhi, India: A			Cross-	
47	cross-sectional study	Sharma	2020	Sectional Study	Medium
	From fever to anti-malarial: the treatment-			Cross-	
48	seeking process in rural Senegal	Smith	2010	Sectional Study	Medium
	Pathways to the first contact with specialist			Cross-	
49	mental health care	Steel	2006	Sectional Study	Medium
	Health care seeking patterns of rifampicin-				
	resistant tuberculosis patients in Harare,				
50	Zimbabwe: A prospective cohort study	Tadokera	2021	Mixed Methods	Medium
	Understanding health care-seeking				
	behaviour of the tribal population in India				
	among those with presumptive TB			Cross-	
51	symptoms	Thomas	2021	Sectional Study	Medium
	Diagnostic pathways and direct medical				
	costs incurred by new adult pulmonary				
	tuberculosis patients prior to anti-				
50	tuberculosis treatment – Tamil Nadu,		00/0	Cross-	
52	India	Veesa	2018	Sectional Study	Medium
	Analysis of care-seeking pathways of			•	
50	tuberculosis patients in Guangxi, China,	\A/_:	0000	Cross-	
53	with and without decentralised tuberculosis	Wei	2009	Sectional Study	Medium

	services				
	Patient care pathways under the model of				
	integrating tuberculosis service with			Cross-	
54	general hospitals in China	Wei	2013	Sectional Study	Medium
	The pathway to diagnosis and treatment				
	for surgically managed lung cancer			Cross-	
55	patients	White	2020	Sectional Study	Medium
	Healthcare utilization for common			_	
	infectious disease syndromes in Soweto			Cross-	
56	and Klerksdorp, South Africa	Wong	2018	Sectional Study	Medium
	Patients pathways to tuberculosis				
	diagnosis and treatment in a fragmented			Owellitetive	
_7	health system: a qualitative study from a	Vellerne	0047	Qualitative	Madium
57	south Indian district	Yellappa	2017	Research	Medium
	Patient pathway analysis of tuberculosis diagnostic delay: a multicentre				
58	retrospective cohort study in China	Zhang	2021	Cohort Study	Medium
50	Care Seeking Behavior of the TB Patients	Zhang	2021	Conort Study	Medium
	who were Registered in an Urban				
	Government Tuberculosis Control in			Cross-	
59	Chennai, Tamilnadu, India	Ananthakrishnan	2012	Sectional Study	Low
	Tuberculosis pathways to care and				
	transmission of multidrug resistance in				
60	India	Atre	2022	Mixed Methods	Low
	Health seeking behaviour, health system				
	experience and tuberculosis case finding			Cross-	
61	in Gambians with cough	Kasse	2006	Sectional Study	Low
	Idiopathic pulmonary fibrosis: Physician				
	and patient perspectives on the pathway to				
	care from symptom recognition to			Cross-	
62	diagnosis and disease burden	Lancaster	2021	Sectional Study	Low
63	Pathways and costs of care for patients	Shete	2015	Cross-	Low

	with tuberculosis symptoms in rural Uganda			Sectional Study	
64	Health seeking and knowledge about tuberculosis among persons with pulmonary symptoms and tuberculosis	Queenthi	2000	Cross-	1
64	cases in Bangalore slums	Suganthi	2008	Sectional Study	Low
65	Health-seeking behavior of COVID-19 cases during the first eight weeks of the outbreak in Singapore: differences between local community and imported cases and having visits to single or multiple healthcare providers	Tav	2022	Cross- Sectional Study	Low
CO		Тау	2022	Sectional Study	Low
	A Cross-Sectional Descriptive Study to Ascertain Factors Influencing Delay in			Creas	
	Diagnosis among Newly Diagnosed	 .		Cross-	.
66	Pulmonary Tuberculosis Patients	Thomas	2022	Sectional Study	Low

458

References

459 1. World Health Organization. Tracking universal health coverage: 2023 global460 monitoring report: World Health Organization; 2023.

461 2. World Health Organization. Global tuberculosis report 2023. 2023.

462 3. Joint United Nations Programme on HIV/AIDS. The path that ends AIDS: 2023463 UNAIDS global AIDS update. 2023.

464 4. Faust L, Naidoo P, Caceres-Cardenas G, et al. Improving measurement of tuberculosis
465 care cascades to enhance people-centred care. *The Lancet Infectious Diseases* 2023.

466 5. MacPherson P, Houben RM, Glynn JR, Corbett EL, Kranzer K. Pre-treatment loss to 467 follow-up in tuberculosis patients in low-and lower-middle-income countries and high-468 burden countries: a systematic review and meta-analysis. *Bulletin of the World Health* 469 *Organization* 2013; **92**: 126-38.

470 6. Arokiasamy P, Uttamacharya, Kowal P, et al. Chronic noncommunicable diseases in 6
471 low-and middle-income countries: findings from wave 1 of the World Health Organization's
472 study on global Ageing and adult health (SAGE). American journal of epidemiology 2017;
473 185(6): 414-28.

Johnson CC, Fonner V, Sands A, et al. To err is human, to correct is public health: a
systematic review examining poor quality testing and misdiagnosis of HIV status. *Journal of the International AIDS Society* 2017; **20**: 21755.

477 8. Mwenesi H, Harpham T, Snow RW. Child malaria treatment practices among 478 mothers in Kenya. *Social science & medicine* 1995; **40**(9): 1271-7.

479 9. Räisänen U, Hunt K. The role of gendered constructions of eating disorders in
480 delayed help-seeking in men: a qualitative interview study. *BMJ open* 2014; 4(4): e004342.

481 10. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and
482 treatment of tuberculosis. *BMC public health* 2008; 8: 1-9.

11. Oga-Omenka C, Tseja-Akinrin A, Sen P, et al. Factors influencing diagnosis and
treatment initiation for multidrug-resistant/rifampicin-resistant tuberculosis in six subSaharan African countries: a mixed-methods systematic review. *BMJ global health* 2020;
5(7): e002280.

Mavhu W, Dauya E, Bandason T, et al. Chronic cough and its association with TB–HIV
co-infection: factors affecting help-seeking behaviour in Harare, Zimbabwe. *Tropical Medicine & International Health* 2010; **15**(5): 574-9.

490 13. Allen H, Wright BJ, Harding K, Broffman L. The role of stigma in access to health care
491 for the poor. *The Milbank Quarterly* 2014; **92**(2): 289-318.

492 14. Cai J, Wang X, Ma A, Wang Q, Han X, Li Y. Factors associated with patient and
493 provider delays for tuberculosis diagnosis and treatment in Asia: a systematic review and
494 meta-analysis. *PloS one* 2015; **10**(3): e0120088.

495 15. Stallworthy G, Dias HM, Pai M. Quality of tuberculosis care in the private health
496 sector. Journal of clinical tuberculosis and other mycobacterial diseases 2020; 20: 100171.

497 16. Carrillo JE, Carrillo VA, Perez HR, Salas-Lopez D, Natale-Pereira A, Byron AT. Defining
498 and targeting health care access barriers. *Journal of health care for the poor and*499 *underserved* 2011; **22**(2): 562-75.

Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for
tuberculosis patients in low-and middle-income countries: a systematic review. *European Respiratory Journal* 2014; 43(6): 1763-75.

503 18. Organization WH. The END TB strategy: World Health Organization; 2015.

504 19. World Health Organization. Interim report: placing people and communities at the 505 centre of health services: WHO global strategy on integrated people-centred health services 506 2016-2026: executive summary: World Health Organization, 2015.

507 20. World Health Organization. World Health Assembly adopts framework on integrated 508 people-centred health services. *World Health Organization* 2016.

509 21. Odone A, Roberts B, Dara M, Van Den Boom M, Kluge H, McKee M. People-and 510 patient-centred care for tuberculosis: models of care for tuberculosis. *The international* 511 *journal of tuberculosis and lung disease* 2018; **22**(2): 133-8.

512 22. Shaller D. Patient-centered care: what does it take?: Commonwealth Fund New York;513 2007.

514 23. World Health Organization. Compendium of data and evidence-related tools for use 515 in TB planning and programming. Compendium of data and evidence-related tools for use 516 in TB planning and programming; 2021.

517 24. Oliver A, Mossialos E. Equity of access to health care: outlining the foundations for 518 action. *Journal of Epidemiology & Community Health* 2004; **58**(8): 655-8.

519 25. Oga-Omenka C, Bada F, Agbaje A, Dakum P, Menzies D, Zarowsky C. Ease and equity 520 of access to free DR-TB services in Nigeria-a qualitative analysis of policies, structures and 521 processes. *International Journal for Equity in Health* 2020; **19**: 1-13.

522 26. Daniels N. Equity of access to health care: some conceptual and ethical issues. *The*523 *Milbank Memorial Fund Quarterly Health and Society* 1982: 51-81.

524 27. Huria L, Lestari BW, Saptiningrum E, et al. Care pathways of individuals with 525 tuberculosis before and during the COVID-19 pandemic in Bandung, Indonesia. *PLOS Global* 526 *Public Health* 2024; **4**(1): e0002251.

527 28. Lestari BW, McAllister S, Hadisoemarto PF, et al. Patient pathways and delays to
528 diagnosis and treatment of tuberculosis in an urban setting in Indonesia. *Lancet Regional*529 *Health-Western Pacific* 2020; 5.

530 29. Oga-Omenka C, Rosapep L, Baruwa E, et al. Individual journeys to tuberculosis care
531 in Nigeria's private sector during the COVID-19 pandemic. *BMJ Global Health* 2024; 9(1):
532 e013124.

533 30. Pinder R, Petchey R, Shaw S, Carter Y. What's in a care pathway? Towards a cultural 534 cartography of the new NHS. *Sociology of health & illness* 2005; **27**(6): 759-79.

535 31. Lismont J, Janssens A-S, Odnoletkova I, vanden Broucke S, Caron F, Vanthienen J. A 536 guide for the application of analytics on healthcare processes: A dynamic view on patient 537 pathways. *Computers in biology and medicine* 2016; **77**: 125-34.

53832.Richter P, Schlieter H. Understanding patient pathways in the context of integrated539health care services-implications from a scoping review. 2019.

540 33. Gartner J-B, Abasse KS, Bergeron F, Landa P, Lemaire C, Côté A. Definition and 541 conceptualization of the patient-centered care pathway, a proposed integrative framework 542 for conceptualization of the patient-centered care pathway.

for consensus: a concept analysis and systematic review. *BMC health services research* 2022;
22(1): 558.

34. Hanson CL, Osberg M, Brown J, Durham G, Chin DP. Conducting patient-pathway
analysis to inform programming of tuberculosis services: methods. *The Journal of infectious diseases* 2017; **216**(suppl_7): S679-S85.

547 35. Hanson C, Osberg M, Brown J, Durham G, Chin DP. Finding the missing patients with 548 tuberculosis: lessons learned from patient-pathway analyses in 5 countries. *The Journal of* 549 *infectious diseases* 2017; **216**(suppl_7): S686-S95.

550 36. Li Y, Ehiri J, Tang S, et al. Factors associated with patient, and diagnostic delays in 551 Chinese TB patients: a systematic review and meta-analysis. *BMC medicine* 2013; **11**: 1-15.

552 37. Obsa MS, Daga WB, Wosene NG, et al. Treatment seeking delay and associated 553 factors among tuberculosis patients attending health facility in Ethiopia from 2000 to 2020: 554 a systematic review and meta analysis. *PloS one* 2021; **16**(7): e0253746.

555 38. Ukwaja KN, Alobu I, Nweke CO, Onyenwe EC. Healthcare-seeking behavior, 556 treatment delays and its determinants among pulmonary tuberculosis patients in rural 557 Nigeria: a cross-sectional study. *BMC health services research* 2013; **13**: 1-9.

55839.Almeida CPBd, Skupien EC, Silva DR. Health care seeking behavior and patient delay559in tuberculosis diagnosis. Cadernos de saude publica 2015; **31**(2): 321-30.

560 40. Fuady A, Houweling TAJ, Mansyur M, Burhan E, Richardus JH. Cost of seeking care for 561 tuberculosis since the implementation of universal health coverage in Indonesia. *BMC* 562 *Health Services Research* 2020; **20**(502).

563 41. Camfield L, Streuli N, Woodhead M. Children's well-being in developing countries: A
564 conceptual and methodological review. *The European Journal of Development Research*565 2010; **22**: 398-416.

42. Wang J, Lloyd-Evans B, Giacco D, et al. Social isolation in mental health: a conceptual
and methodological review. *Social psychiatry and psychiatric epidemiology* 2017; **52**: 145161.

Kallio H, Pietilä AM, Johnson M, Kangasniemi M. Systematic methodological review:
developing a framework for a qualitative semi-structured interview guide. *Journal of advanced nursing* 2016; **72**(12): 2954-65.

572 44. Frederiksen L, Phelps SF, Kimmons R. Introduction to literature reviews. *Rapid*573 academic writing [document on the Internet] c2018 [cited 2021 Oct 13] Available from:
574 <u>https://edtechbooks</u> org/pdfs/mobile/rapidwriting/lit_rev_intro pd f 2018.

575 45. Hulland J. Conceptual review papers: revisiting existing research to develop and 576 refine theory. *AMS Review* 2020; **10**(1): 27-35.

577 46. Jit M, Ng DHL, Luangasanatip N, et al. Quantifying the economic cost of antibiotic 578 resistance and the impact of related interventions: rapid methodological review, conceptual 579 framework and recommendations for future studies. *BMC medicine* 2020; **18**: 1-14.

580 47. Campbell M, Egan M, Lorenc T, et al. Considering methodological options for reviews
581 of theory: illustrated by a review of theories linking income and health. *Systematic reviews*582 2014; **3**: 1-11.

583 48. Mbuagbaw L, Lawson DO, Puljak L, Allison DB, Thabane L. A tutorial on 584 methodological studies: the what, when, how and why. *BMC Medical Research* 585 *Methodology* 2020; **20**: 1-12.

586 49. Munn Z, Stern C, Aromataris E, Lockwood C, Jordan Z. What kind of systematic 587 review should I conduct? A proposed typology and guidance for systematic reviewers in the 588 medical and health sciences. *BMC medical research methodology* 2018; **18**: 1-9.

589 50. Lilford RJ, Richardson A, Stevens A, et al. Issues in methodological research: 590 perspectives from researchers and commissioners. 2001.

591 51. Joanna Briggs Institute. Critical Appraisal Tools. 2020. <u>https://jbi.global/critical-</u> 592 <u>appraisal-tools</u>.

593 52. Hong QN, Fàbregues S, Bartlett G, et al. The Mixed Methods Appraisal Tool (MMAT) 594 version 2018 for information professionals and researchers. *Education for information* 2018; 595 **34**(4): 285-91.

53. Yang W-T, Gounder CR, Akande T, et al. Barriers and delays in tuberculosis diagnosis
and treatment services: does gender matter? *Tuberculosis research and treatment* 2014;
2014.

599 54. Subbaraman R, Jhaveri T, Nathavitharana RR. Closing gaps in the tuberculosis care 600 cascade: an action-oriented research agenda. *Journal of clinical tuberculosis and other* 601 *mycobacterial diseases* 2020; **19**: 100144.

55. Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV
care in the United States: from cascade to continuum to control. *Clinical infectious diseases*2013; 57(8): 1164-71.

605 56. Oga-Omenka C, Boffa J, Kuye J, Dakum P, Menzies D, Zarowsky C. Understanding the
606 gaps in DR-TB care cascade in Nigeria: A sequential mixed-method study. *Journal of Clinical*607 *Tuberculosis and Other Mycobacterial Diseases* 2020; **21**: 100193.

57. Baru RV. Disease and Suffering: Towards a Framework for Understanding Health
Seeking Behavior. *Indian Anthropologist* 2005: 45-52.

58. Lestari BW, McAllister S, Hadisoemarto PF, et al. Patient pathways and delays to
diagnosis and treatment of tuberculosis in an urban setting in Indonesia. *The Lancet Regional Health–Western Pacific* 2020; 5.

59. Ahmad RA, Mahendradhata Y, Utarini A, de Vlas SJ. Diagnostic delay amongst
tuberculosis patients in Jogjakarta Province, Indonesia is related to the quality of services in
DOTS facilities. *Tropical Medicine & International Health* 2011; 16(4): 412-23.

616 60. Ansar A, Lewis V, McDonald CF, Liu C, Rahman MA. Duration of intervals in the care 617 seeking pathway for lung cancer in Bangladesh: A journey from symptoms triggering 618 consultation to receipt of treatment. *PloS one* 2021; **16**(9): e0257301.

619 61. Asres A, Jerene D, Deressa W. Delays to anti-tuberculosis treatment intiation among 620 cases on directly observed treatment short course in districts of southwestern Ethiopia: a 621 cross sectional study. *BMC Infect Dis* 2019; **19**(1): 481.

622 62. Atre SR, Jagtap JD, Faqih MI, et al. Tuberculosis pathways to care and transmission of 623 multidrug resistance in India. *American Journal of Respiratory and Critical Care Medicine* 624 2022; **205**(2): 233-41.

625 63. Ayisi JG, Hoog AHv, Agaya JA, et al. Care seeking and attitudes towards treatment 626 compliance by newly enrolled tuberculosis patients in the district treatment programme in 627 rural western Kenya: a qualitative study. *BMC Public Health* 2011; **11**(515).

628 64. Bronner Murrison L, Ananthakrishnan R, Swaminathan A, et al. How do patients 629 access the private sector in Chennai, India? An evaluation of delays in tuberculosis 630 diagnosis. *Int J Tuberc Lung Dis* 2016; **20**(4): 544-51.

631 65. Diallo A, Combary A, Veronese V, et al. Delays in TB Diagnosis and Treatment 632 Initiation in Burkina Faso during the COVID-19 Pandemic. *Trop Med Infect Dis* 2022; **7**(9).

633 66. Gothankar JS, Patil UP, Gaikwad SR, Kamble SB. Care seeking behaviour and various 634 delays in tuberculosis patients registered under RNTCP in Pune city. *Indian Journal of* 635 *Community Health* 2016; **28**(1): 34-9.

636 67. Guan Z, Webber C, Flemming JA, et al. Real-world colorectal cancer diagnostic 637 pathways in Ontario, Canada: A population-based study. *European Journal of Cancer Care* 638 2022; **31**(5): 1-13.

639 68. Herdman MT, Maude RJ, Chowdhury MS, et al. The relationship between poverty 640 and healthcare seeking among patients hospitalized with acute febrile illnesses in 641 Chittagong, Bangladesh. *PLoS One* 2016; **11**(4): e0152965.

642 69. Kasse Y, Jasseh M, Corrah T, et al. Health seeking behaviour, health system
643 experience and tuberculosis case finding in Gambians with cough. *BMC Public Health* 2006;
644 6(143).

Kumawat A, Chakraborti A, Kumar S, et al. Study of factors leading to treatment
delay in new sputum positive pulmonary tuberculosis patients and its impact on sputum
conversion. *Tropical Doctor*.

Lancaster L, Bonella F, Inoue Y, et al. Idiopathic pulmonary fibrosis: Physician and
patient perspectives on the pathway to care from symptom recognition to diagnosis and
disease burden. *Respirology (Carlton, Vic)* 2022; **27**(1): 66-75.

651 72. Laokri S, Drabo MK, Weil O, Kafando B, Dembélé SM, Dujardin B. Patients are paying
652 too much for tuberculosis: a direct cost-burden evaluation in Burkina Faso. *PLoS One* 2013;
653 8(2): e56752.

Maamari F. Case-finding tuberculosis patients: diagnostic and treatment delays and
their determinants. *Eastern Mediterranean Health Journal* 2008; **14**(3): 531-45.

656 74. Mercer CH, Sutcliffe L, Johnson AM, et al. How much do delayed healthcare seeking,
657 delayed care provision, and diversion from primary care contribute to the transmission of
658 STIS? SEXUALLY TRANSMITTED INFECTIONS 2007; 83(5): 400-5.

Mistry N, Lobo E, Shah S, Rangan S, Dholakia Y. Pulmonary tuberculosis in Patna,
India: Durations, delays, and health care seeking behaviour among patients identified
through household surveys. *Journal of Epidemiology and Global Health* 2017; 7(4): 241-8.

662 76. Mistry N, Rangan S, Dholakia Y, Lobo E, Shah S, Patil A. Durations and Delays in Care
663 Seeking, Diagnosis and Treatment Initiation in Uncomplicated Pulmonary Tuberculosis
664 Patients in Mumbai, India. *PLoS One* 2016; **11**(3).

77. Priya R, Kalpita S, Bhaskaran U, Abhinav P, Abhirami N. Patient treatment pathways
of multidrug-resistant tuberculosis cases in coastal South India: road to a drug resistant
tuberculosis center [version 5; peer review: 2 approved, 1 approved with reservations]. *F1000Research* 2021; **8**(498).

78. Rajeswari R, Chandrasekaran V, Suhadev M, Sivasubramaniam S, Sudha G, Renu G.
Factors associated with patient and health system delays in the diagnosis of tuberculosis in
South India. *International Journal of Tuberculosis and Lung Disease* 2002; 6(9): 789-95.

572 79. Salaniponi FM, Harries AD, Banda HT, et al. Care seeking behaviour and diagnostic
573 processes in patients with smear-positive pulmonary tuberculosis in Malawi. *Int J Tuberc*574 *Lung Dis* 2000; 4(4): 327-32.

80. Shah S, Shah S, Rangan S, et al. Effect of public-private interface agency in Patna and
Mumbai, India: Does it alter durations and delays in care seeking for drug-sensitive
pulmonary tuberculosis? *Gates Open Res* 2020; **4**: 32.

81. Sharma N, Bhatnagar A, Basu S, et al. A comparison of patient treatment pathways
among multidrug-resistant and drug-sensitive TB cases in Delhi, India: A cross-sectional
study. *Indian J Tuberc* 2020; 67(4): 502-8.

681 82. Steel Z, McDonald R, Silove D, et al. Pathways to the first contact with specialist 682 mental health care. *Australian & New Zealand Journal of Psychiatry* 2006; **40**(4): 347-54.

83. Tay M, Ang L, Wei W, Lee VJM, Leo Y, Toh MPHS. Health-seeking behavior of COVID19 cases during the first eight weeks of the outbreak in Singapore: differences between local
community and imported cases and having visits to single or multiple healthcare providers. *BMC Public Health* 2022; **22**(239).

84. Thomas N, Rajalingam R, Vallabhaneni V, Varghese J. A Cross-Sectional Descriptive
Study to Ascertain Factors Influencing Delay in Diagnosis among Newly Diagnosed
Pulmonary Tuberculosis Patients. *Indian Journal of Respiratory Care* 2022; **11**(4): 341-8.

85. Veesa KS, John KR, Moonan PK, et al. Diagnostic pathways and direct medical costs
incurred by new adult pulmonary tuberculosis patients prior to anti-tuberculosis treatment Tamil Nadu, India. *PLoS One* 2018; **13**(2): e0191591.

86. Viney KA, Johnson P, Tagaro M, et al. Tuberculosis patients' knowledge and beliefs
about tuberculosis: a mixed methods study from the Pacific Island nation of Vanuatu. BMC *Public Health* 2014; **14**.

696 87. Wei X, Zou G, Yin J, Walley J, Sun Q. Comparing patient care seeking pathways in
697 three models of hospital and TB programme collaboration in China. *BMC Infectious Diseases*698 2013; **13**(93).

699 88. Wei XL, Liang XY, Walley JD, Liu FY, Dong BQ. Analysis of care-seeking pathways of 700 tuberculosis patients in Guangxi, China, with and without decentralised tuberculosis 701 services. *International Journal of Tuberculosis and Lung Disease* 2009; **13**(4): 514-20.

White V, Bergin RJ, Thomas RJ, Whitfield K, Weller D. The pathway to diagnosis and
treatment for surgically managed lung cancer patients. *Family practice* 2020; **37**(2): 234-41.

90. Yellappa V, Lefèvre P, Battaglioli T, Devadasan N, Van der Stuyft P. Patients pathways
to tuberculosis diagnosis and treatment in a fragmented health system: a qualitative study
from a south Indian district. *BMC public health* 2017; **17**(1): 1-10.

707 91. Zhang L, Weng T, Wang H, et al. Patient pathway analysis of tuberculosis diagnostic
708 delay: a multicentre retrospective cohort study in China. *Clinical Microbiology and Infection*709 2021; 27(7): 1000-6.

Abimbola S, Ukwaja KN, Onyedum CC, Negin J, Jan S, Martiniuk AL. Transaction costs
of access to health care: Implications of the care-seeking pathways of tuberculosis patients
for health system governance in Nigeria. *Glob Public Health* 2015; **10**(9): 1060-77.

93. Asbroek AHAt, Bijlsma MW, Malla P, Shrestha B, Delnoij DMJ. The road to
tuberculosis treatment in rural Nepal: a qualitative assessment of 26 journeys. *BMC Health Services Research* 2008; 8(7).

94. Aye R, Wyss K, Abdualimova H, Saidaliev S. Patient's site of first access to health
system influences length of delay for tuberculosis treatment in Tajikistan. BMC Health
Services Research 2010; 10(10).

95. Benjarattanaporn P, Lindan CP, Mills S, et al. Men with sexually transmitted diseases
in Bangkok: where do they go for treatment and why? *Aids* 1997; **11**(Supplement1): S87S95.

96. Bhattacharya Chakravarty A, Rangan S, Dholakia Y, et al. Such a long journey: What
health seeking pathways of patients with drug resistant tuberculosis in Mumbai tell us. *PLoS One* 2019; **14**(1): e0209924.

725 97. Kallander K, Counihan H, Cerveau T, Mbofana F. Barriers on the pathway to survival
726 for children dying from treatable illnesses in Inhambane province, Mozambique. *Journal of*727 *Global Health* 2019; 9(1).

98. Mesfin MM, Newell JN, Walley JD, Gessessew A, Madeley RJ. Delayed consultation
among pulmonary tuberculosis patients: a cross sectional study of 10 DOTS districts of
Ethiopia. *BMC Public Health* 2009; **9**(53).

731 99. Millar KR, McCutcheon J, Coakley EH, et al. Patterns and predictors of malaria care-732 seeking, diagnostic testing, and artemisinin-based combination therapy for children under 733 five with fever in Northern Nigeria: a cross-sectional study. *Malaria Journal* 2014; **13**(447).

Pati S, Sahoo KC, Samal M, et al. Care-seeking pathways, care challenges, and coping
experiences of rural women living with rheumatoid arthritis in Odisha, India. *Primary Health Care Research & Development* 2019; 20.

101. Renthlei L, Murhekar MV. Health-seeking behaviour for febrile illness in malariaendemic Kolasib district, Mizoram, India. *International Health (RSTMH)* 2012; 4(4): 314-9.

102. Shete PB, Haguma P, Miller CR, et al. Pathways and costs of care for patients with
tuberculosis symptoms in rural Uganda. *International Journal of Tuberculosis and Lung Disease* 2015; **19**(8): 912-7.

Tadokera R, Huo S, Theron G, Timire C, Manyau-Makumbirofa S, Metcalfe JZ. Health
care seeking patterns of rifampicin-resistant tuberculosis patients in Harare, Zimbabwe: A
prospective cohort study. *PLoS One* 2021; **16**(7).

Thomas BE, Thiruvengadam K, Raghavi S, et al. Understanding health care-seeking
behaviour of the tribal population in India among those with presumptive TB symptoms. *PLoS One* 2021; **16**(5).

105. Wei X, Yin J, Zou G, et al. Patient care pathways under the model of integrating
tuberculosis service with general hospitals in China. *Tropical Medicine & International Health* 2013; **18**(11): 1392-9.

106. Wong K, Mollendorf Cv, Martinson N, et al. Healthcare utilization for common
infectious disease syndromes in Soweto and Klerksdorp, South Africa. *Pan African Medical Journal* 2018; **30**: 271.

107. Almeida CP, Skupien EC, Silva DR. Health care seeking behavior and patient delay in
tuberculosis diagnosis. *Cad Saude Publica* 2015; **31**(2): 321-30.

108. Ananthakrishnan R, Jeyaraju AR, Palani G, Sathiyasekaran BWC. Care Seeking
Behavior of the TB Patients who were Registered in an Urban Government Tuberculosis
Control in Chennai, Tamilnadu, India. *Journal of Clinical and Diagnostic Research* 2012; 6(6):
990-3.

Charles N, Thomas B, Watson B, Raja Sakthivel M, Chandrasekeran V, Wares F. Care
seeking behavior of chest symptomatics: a community based study done in South India after
the implementation of the RNTCP. *PLoS One* 2010; 5(9).

763110.Suganthi P, Chadha VK, Ahmed J, et al. Health seeking and knowledge about764tuberculosis among persons with pulmonary symptoms and tuberculosis cases in Bangalore

slums. International Journal of Tuberculosis and Lung Disease 2008; **12**(11): 1268-73.

766 111. Smith LA, Bruce J, Gueye L, et al. From fever to anti-malarial: the treatment-seeking
767 process in rural Senegal. *Malaria Journal* 2010; **9**(333).

The term of the term of the term of the term of the term of the term of the term of the term of term

113. Ahmed SM, Rashidul H, Ubydul H, Awlad H. Knowledge on the transmission,
prevention and treatment of malaria among two endemic populations of Bangladesh and
their health-seeking behaviour. *Malaria Journal* 2009; 8(173).

114. Auer C, Kiefer S, Zuske M, et al. Health-seeking behaviour and treatment delay in
patients with pulmonary tuberculosis in Switzerland: some slip through the net. Swiss Med
Wkly 2018; 148: w14659.

115. Chadha VK, Praseeja P, Srivastava R, et al. Pre-treatment delay and out of pocket
expenses by notified new tuberculosis patients in an Indian mega city. *Indian J Tuberc* 2022;
69(4): 446-52.

116. Ku CC, Chen CC, Dixon S, Lin HH, Dodd PJ. Patient pathways of tuberculosis careseeking and treatment: an individual-level analysis of National Health Insurance data in
Taiwan. *BMJ Global Health* 2020; 5(6).

117. Ukwaja KN, Alobu I, Nweke CO, Onyenwe EC. Healthcare-seeking behavior,
treatment delays and its determinants among pulmonary tuberculosis patients in rural
Nigeria: a cross-sectional study. *BMC Health Services Research* 2013; 13(25).

Pati S, Hussain MA, Chauhan AS, Mallick D, Nayak S. Patient navigation pathway and
barriers to treatment seeking in cancer in India: a qualitative inquiry. *Cancer Epidemiology*2013; **37**(6): 973-8.

119. Hossain I, Hill P, Bottomley C, et al. Healthcare seeking and access to care for
pneumonia, sepsis, meningitis, and malaria in rural Gambia. *American Journal of Tropical Medicine and Hygiene* 2022; **106**(2): 446-53.

791 120. Omale UI, Oka OU, Okeke IM, et al. Demand for malaria rapid diagnostic test, health
792 care-seeking behaviour, and drug use among rural community members with fever or
793 malaria-like illness in Ebonyi state, Nigeria: a cross-sectional household survey. BMC Health
794 Services Research 2021; 21(1).

795 121. Price J, Willcox M, Dlamini V, et al. Care-seeking during fatal childhood illness in rural
796 South Africa: a qualitative study. *BMJ Open* 2021; **11**(4).